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A B S T R A C T
Background
This is an updated version of the original Cochrane Review published in Issue 12, 2016. This review is one in a series of Cochrane
Reviews investigating pair-wise monotherapy comparisons.
Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked
seizures. It is believed that with effective drug treatment, up to 70% of individuals with active epilepsy have the potential to become
seizure-free and go into long-term remission shortly after starting drug therapy, the majority of which may be able to achieve remission
with a single antiepileptic drug (AED).
The correct choice of first-line AED for individuals with newly diagnosed seizures is of great importance and should be based on the
highest-quality evidence available regarding the potential benefits and harms of various treatments for an individual.
Topiramate and carbamazepine are commonly used AEDs. Performing a synthesis of the evidence from existing trials will increase the
precision of results of outcomes relating to efficacy and tolerability, and may help inform a choice between the two drugs.
Objectives
To review the time to treatment failure, remission and first seizure with topiramate compared with carbamazepine when used as
monotherapy in people with focal onset seizures (simple or complex focal and secondarily generalised), or generalised onset tonic-clonic
seizures (with or without other generalised seizure types).
Search methods
For the latest update we searched theCochrane Register of Studies (CRSWeb), which includes the Cochrane EpilepsyGroup Specialized
Register and the Cochrane Central Register of Controlled Trials (CENTRAL); MEDLINE (Ovid); ClinicalTrials.gov; and the WHO
International Clinical Trials Registry Platform (ICTRP) to 22 May 2018. We imposed no language restrictions. We also contacted
pharmaceutical companies and trial investigators.
Selection criteria
Randomised controlled trials (RCTs) comparing monotherapy with either topiramate or carbamazepine in children or adults with focal
onset seizures or generalised onset tonic-clonic seizures (with or without other generalised seizure types).
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Data collection and analysis
This was an individual participant data (IPD), review. Our primary outcome was time to treatment failure. Our secondary outcomes
were time to first seizure post-randomisation, time to six-month remission, time to 12-month remission, and incidence of adverse events.
We used Cox proportional hazards regression models to obtain trial-specific estimates of hazard ratios (HRs), with 95% confidence
intervals (CIs), using the generic inverse variance method to obtain the overall pooled HR and 95% CI.
Main results
IPD were available for 1151 of 1239 eligible individuals from two of three eligible studies (93% of the potential data). A small
proportion of individuals recruited into these trials had ’unclassified seizures;’ for analysis purposes, these individuals are grouped with
those with generalised onset seizures. For remission outcomes, a HR < 1 indicated an advantage for carbamazepine, and for first seizure
and treatment failure outcomes, a HR < 1 indicated an advantage for topiramate.
The main overall results for the primary outcome, time to treatment failure, given as pooled HR adjusted for seizure type were: time
to failure for any reason related to treatment 1.16 (95% CI 0.97 to 1.38); time to failure due to adverse events 1.02 (95% CI 0.82
to 1.27); and time to failure due to lack of efficacy 1.46 (95% CI 1.08 to 1.98). Overall results for secondary outcomes were time to
first seizure 1.11 (95% CI 0.96 to 1.29); and time to six-month remission 0.88 (0.76 to 1.01). There were no statistically significant
differences between the drugs. A statistically significant advantage for carbamazepine was shown for time to 12-month remission: 0.84
(95% CI 0.71 to 0.99).
The results of this review are applicable mainly to individuals with focal onset seizures; 81% of individuals included within the
analysis experienced seizures of this type at baseline. For individuals with focal onset seizures, a statistically significant advantage for
carbamazepine was shown for time to failure for any reason related to treatment (HR 1.21, 95% CI 1.01 to 1.46), time to treatment
failure due to lack of efficacy (HR 1.47, 95% CI 1.07 to 2.02), and time to 12-month remission (HR 0.82, 95% CI 0.69 to 0.99).
There was no statistically significant difference between topiramate and carbamazepine for ’time to first seizure’ and ’time to six-month
remission’.
Evidence for individuals with generalised tonic-clonic seizures (9% of participants contributing to the analysis), and unclassified seizure
types (10% of participants contributing to the analysis) was very limited; no statistically significant differences were found but CIs were
wide; therefore we cannot exclude an advantage to either drug, or a difference between drugs.
The most commonly reported adverse events with both drugs were drowsiness or fatigue, “pins and needles” (tingling sensation),
headache, gastrointestinal disturbance and anxiety or depression. The rate of adverse events was similar across the two drugs.
We judged the methodological quality of the included trials generally to be good; however, there was some evidence that the open-label
design of the larger of the two trials may have influenced the treatment failure rate within the trial. Hence, we judged the certainty of
the evidence for treatment failure to be moderate for individuals with focal onset seizures and low for individuals with generalised onset
seizures. For efficacy outcomes (first seizure, remission), we judged the certainty of evidence from this review to be high for individuals
with focal onset seizures and moderate for individuals with generalised onset or unclassified seizures.
Authors’ conclusions
For individuals with focal onset seizures, there is moderate-certainty evidence that carbamazepine is less likely to be withdrawn and high-
certainty evidence that 12-month remission will be achieved earlier than with topiramate. We did not find any differences between the
drugs in terms of the other outcomes measured in the review and for individuals with generalised tonic-clonic seizures or unclassified
epilepsy; however, we encourage caution in the interpretation of results including small numbers of participants with these seizure
types.
Future trials should be designed to the highest quality possible and take into consideration masking, choice of population, classification
of seizure type, duration of follow-up, choice of outcomes and analysis, and presentation of results.
P L A I N L A N G U A G E S U M M A R Y
Topiramate versus carbamazepine as single drug treatment for epilepsy
This is an updated version of the Cochrane Review previously published in Issue 12, 2016 of the Cochrane Database of Systematic
Reviews.
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Background
Epilepsy is a common disorder of the nervous system in which abnormal electrical discharges from the brain cause recurrent seizures
(physical convulsions or thought disturbances or a combination of these symptoms). We studied two types of epileptic seizures in this
review: generalised onset seizures in which electrical discharges begin in one part of the brain and move throughout the brain, and focal
onset seizures (also known as partial onset seizures) in which the seizure is generated in and affects the same part of the brain. Focal
onset seizures may become generalised (secondary generalisation) and move from one part of the brain to throughout the brain. Up
to 70% of individuals with active epilepsy have the potential to go into long-term remission shortly after starting drug therapy and
around 70% of these individuals can achieve seizure freedom using a single antiepileptic drug.
This review applies to people with focal onset seizures (with or without secondary generalisation) and people with tonic-clonic seizures,
a specific type of generalised onset seizure, as the recommended treatments for these seizure types are similar.
Objective
Topiramate and carbamazepine are commonly used treatments for individuals with epilepsy. The aim of this review was to compare
how effective these drugs are at controlling recently diagnosed seizures, whether they are associated with side effects that may result in
individuals stopping the drug and to inform a choice between these drugs.
Methods
We assessed the evidence from three clinical trials that compared topiramate with carbamazepine. We were able to combine data for
1151 people from two trials; we were not able to use the data from the remaining trial, which included 88 participants.
Results
Most (81%) of the people included in the two trials experienced focal seizures, so the results of this review apply mainly to people with
this seizure type. Many of the remaining 19% of people experienced a seizure type which was difficult to classify as focal or generalised
(unclassified seizures). Considering only people with focal seizures, the results showed that those taking carbamazepine were more likely
to take their treatment for longer and to achieve a remission of 12 months duration earlier than those taking topiramate. No differences
were found between the drugs in individuals with generalised onset or unclassified epilepsy.
The most common side effects reported by the participants during the trials were fatigue, ’pins and needles’ (tingling sensation),
headache, gastrointestinal problems and anxiety or depression. These side effects were reported a similar number of times by people
taking topiramate or carbamazepine.
Certainty of the evidence
For people with focal onset seizures, we judged the certainty of the evidence to be moderate to high. The design of the trials (whether
the people and treating clinicians knew which drug they were taking) may have influenced how long a participant stayed on their
treatment. For the small number of people with generalised onset or unclassified seizures, we judged the certainty of the evidence to be
low to moderate. The evidence is current to May 2018.
Conclusions
Carbamazepine is currently recommended by experts for the treatment of individuals who are newly diagnosed with focal onset seizures
and the results of this review do not provide any evidence to contradict this. More information is needed for people with generalised
onset or unclassified seizures. All future trials comparing these drugs, or any other antiepileptic drugs, should be designed using high-
quality methods, and the types of seizure of the people included in any trials should be classified very carefully to ensure that the results
are of high quality.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Topiramate compared with carbamazepine for epilepsy (time to treatment failure)
Population: adults and children with newly onset focal or generalised epilepsy
Settings: outpat ients
Intervention: topiramate
Comparison: carbamazepine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Carbamazepine Topiramate
Time to treatment fail-
ure (any reason related
to treatment)
All participants - adjusted
by seizure type
Range of follow-up: 0 to
2420 days
The median t ime to
treatment failure was
1144 days in the carba-
mazepine group
The median t ime to
treatment failure was
614 days (530 days
shorter) in the topira-
mate group
HR 1.16
(0.97 to 1.38)a
1129
(2 studies)
⊕⊕⊕©
Moderateb
HR < 1 indicates a clin-
ical advantage for topi-
ramate
Treatment failure due
to lack of ef f icacy (HR
1.46, 95% CI 1.08 to 1.
98, P = 0.01), occurred
signif icant ly earlier on
topiramate compared
to carbamazepine and
there was no dif ference
between the drugs for
treatment failure due to
adverse events (HR 1.
02, 95%CI 0.82 to 1.27,
P = 0.84)
Time to treatment fail-
ure (any reason related
to treatment) Subgroup:
focal onset seizures
Range of follow-up: 0 to
The median t ime to
treatment failure was
1149 days in the carba-
mazepine group
The median t ime to
treatment failure was
505 days (644 days
shorter) in the topira-
mate group
HR 1.21
(1.01 to 1.46)
937
(2 studies)
⊕⊕⊕©
Moderateb
HR < 1 indicates a clin-
ical advantage for topi-
ramate
Treatment failure due
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2420 days to lack of ef f icacy (HR
1.47, 95% CI 1.07 to 2.
02, P = 0.02), occurred
signif icant ly earlier on
topiramate compared
to carbamazepine and
there was no dif ference
between the drugs for
treatment failure due to
adverse events (HR 1.
08, 95%CI 0.85 to 1.36,
P = 0.53)
Time to treatment fail-
ure (any reason related
to treatment)
Subgroup: generalised on-
set tonic-clonic seizures or
unclassified epilepsy
Range of follow-up: 0 to
1446 days
The median t ime to
treatment failure was
1056 days in the carba-
mazepine group
The median t ime to
treatment failure was
1448 days (392 days
longer) in the topira-
mate group
HR 0.88
(0.56 to 1.39)
192
(2 studies)
⊕⊕©©
Lowc,d
HR < 1 indicates a clin-
ical advantage for topi-
ramate
There was also no sta-
t ist ically signif icant dif -
ference between drugs
in treatment failure due
to adverse events (HR
0.72, 95% CI 0.39 to 1.
31, P = 0.28) or treat-
ment failure due to lack
of ef f icacy (HR 1.41,
95%CI 0.54 to 3.67, P =
0.48)
* Illustrat ive risks in the topiramate and carbamazepine groups are calculated at the median t ime to treatment failure (i.e. the t ime to 50%of part icipants failing or withdrawing
f rom allocated treatment) within each group across all t rials. The relat ive ef fect (pooled hazard rat io) shows the comparison of ’t ime to treatment failure’ between the
treatment groups
CI: conf idence interval; HR: hazard rat io
GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect
Moderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low certainty: we are very uncertain about the est imate5
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aPooled HR for all part icipants adjusted for seizure type.
bDowngraded once for risk of bias; the larger of the two studies was open-label (SANAD A 2007), and may have inf luenced
the withdrawal rates of the trial.
cDowngraded once for imprecision and applicability; lim ited information on generalised seizure types and most part icipants
do not have a classif ied seizure type in this subgroup so the interpretat ion of this seizure type is unclear.
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B A C K G R O U N D
This is an updated version of the Cochrane Review previously
published in Issue 12, 2016 of theCochrane Database of Systematic
Reviews (Nolan 2016a).
Description of the condition
Epilepsy is a common neurological condition in which abnormal
electrical discharges from the brain cause recurrent, unprovoked
seizures. Epilepsy is a disorder comprising many heterogeneous
seizure types, with an estimated incidence of 33 to 57 per 100,000
person-years worldwide (Annegers 1999; Hirtz 2007;MacDonald
2000; Olafsson 2005; Sander 1996), accounting for between 1%
and 5% of the global burden of disease (Murray 1994; Sander
1996). The lifetime risk of epilepsy onset is estimated to be 1300 to
4000 per 100,000 person-years (Hauser 1993; Juul-Jenson 1983).
Recently, around 42 million individuals worldwide were reported
to have active epilepsy worldwide (Global Burden ofDisease Study
2013); however, country-specific prevalence and incidence rates
are thought to vary considerably, with higher rates in resource-poor
countries (Bell 2014). It is thought that the lifetime prevalence
could be as much as 70 million people worldwide (Ngugi 2010).
Experts believe that with effective drug treatment, up to 70% of
individuals with active epilepsy have the potential to go into long-
term remission shortly after starting drug therapy (Cockerell 1995;
Hauser 1993; Sander 2004), and around 70% of these individ-
uals can achieve seizure freedom using antiepileptic drug (AED)
monotherapy (Cockerell 1995).CurrentUKNational Institute for
Health and Care Excellence (NICE) guidelines recommend that
both adults and children with epilepsy be treated with monother-
apy, wherever possible (NICE 2012). The remaining 30% of in-
dividuals who experience refractory or drug-resistant seizures will
often require treatment with combinations of AEDs or alternative
therapies, such as epilepsy surgery (Kwan 2000).
We studied two seizure types in this review; generalised onset
seizures inwhich electrical discharges begin in one part of the brain
and move throughout the brain, and focal onset seizures in which
the seizure is generated in and affects one part of the brain (the
whole hemisphere of the brain or part of a lobe of the brain).
Description of the intervention
Carbamazepine was amongst the earliest of the ’traditional’ drugs
licensed for the treatment of epileptic seizures and has been com-
monly used as monotherapy for focal onset and generalised on-
set seizures for over 30 years (Shakir 1980). Topiramate is a
second-generation AED, licensed as monotherapy for epileptic
seizures following demonstrations of efficacy in dose-controlled
studies compared with ’traditional’ AEDs, such as carbamazepine
and sodium valproate (Gilliam 2003; Privitera 2003; SANAD
A 2007; SANAD B 2007). Comparative trials have also shown
newer AEDs, such as topiramate, to be generally well-tolerated
as monotherapy in both adults and children and associated with
fewer adverse events, fewer serious adverse events, and fewer drug
interactions with concomitant AEDs and other concomitant med-
ications than traditional first-line AEDs, such as carbamazepine
(French 2007).
Evidence regarding the teratogenic effects (disturbances to foetal
development) of carbamazepine and topiramate is inconclusive.
Experts believe that the risk of congenital malformation may be
higher in women taking carbamazepine than in the general popu-
lation (Meador 2008; Morrow 2006; Weston 2016), and studies
have associated carbamazepine with neural tube defects (Matlow
2012). The risk of malformations is thought to be lower for
women taking topiramate monotherapy than for those taking car-
bamazepine monotherapy (Hunt 2008; Meador 2008; Morrow
2006), but the risk of malformation may increase in women tak-
ing topiramate as a component of polytherapy (Hunt 2008). It is
unclear whether taking topiramate or carbamazepine during preg-
nancy has any negative neurodevelopmental effects on the child
(Bromley 2014).
Current UK guidelines for adults and children recommend carba-
mazepine or lamotrigine as a first-line treatment for newly onset
focal seizures, and sodium valproate for newly onset generalised
tonic-clonic seizures (with or without other generalised seizure
types) (NICE 2012). Carbamazepine may be a suitable second-
line treatment for generalised onset tonic-clonic seizures, but may
exacerbate myoclonic or absence seizures (Liporace 1994; Shields
1983; Snead 1985). Topiramate is mainly recommended for ad-
junctive use, but may be considered as a second-line treatment
for both focal and generalised seizures if first-line treatments have
failed or are unsuitable.
How the intervention might work
AEDs suppress seizures by reducing neuronal excitability (disrup-
tion of the usual mechanisms of a neurone within the brain, which
may lead to an epileptic seizure) (MacDonald 1995). Both topi-
ramate and carbamazepine are considered broad-spectrum treat-
ments, suitable formany seizure types. Carbamazepine has an anti-
convulsant mechanism that works by blocking ion channels, bind-
ing with neurotransmitter receptors, or inhibiting the metabolism
or reuptake of neurotransmitters (Brodie 1996; Ragsdale 1991).
The mechanisms of action of topiramate are not fully understood
butmay include the inhibition of voltage-dependent sodiumchan-
nels and the enhancement or modulation of gamma-aminobu-
tyric acid-A by action at a unique modulatory site (Coulter 1993;
White 1997).
Why it is important to do this review
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With evidence that up to 70% of individuals with active epilepsy
have the potential to go into long-term remissionof seizures shortly
after starting drug therapy (Cockerell 1995; Hauser 1993; Sander
2004), the correct choice of first-line antiepileptic therapy for in-
dividuals with newly diagnosed seizures is of great importance. It
is important that clinicians are able to choose themost appropriate
AED for an individual using the highest-quality evidence available
regarding the potential benefits and harms of various treatments.
It is also important to compare the efficacy and tolerability of
AEDs appropriate to given seizure types. Performing a synthesis of
the evidence from existing trials will increase the precision of the
results of outcomes relating to efficacy and tolerability, and may
help inform a choice between drugs.
There are difficulties in undertaking a systematic review of epilepsy
monotherapy trials, as the important efficacy outcomes require
analysis of time-to-event data (e.g. time to first seizure after ran-
domisation). Although methods have been developed to synthe-
sise time-to-event data using summary information (Parmar 1998;
Williamson 2002), the appropriate statistics are not commonly
reported in published epilepsy trials (Nolan 2013a). Furthermore,
although most epilepsy monotherapy trials collect seizure data,
the definitions and reporting of outcomes are inconsistent. For
example, trials may report time to 12-month remission but not
time to first seizure or vice versa, or some trials may define time to
first seizure from the date of randomisation whereas others use the
date of achieving maintenance dose. Trial investigators have also
adopted differing approaches to data analysis, particularly with
respect to the censoring of time-to event data. For these reasons,
we performed this review using individual participant data (IPD),
which helps to overcome these problems. This review is one in a se-
ries of Cochrane IPD reviews investigating pair-wise monotherapy
comparisons (Marson 2000; Nevitt 2017b; Nevitt 2018a; Nevitt
2018b; Nevitt 2018c; Nevitt 2018d; Nolan 2013b). These data
have also been included in IPD network meta-analyses of AED
monotherapy (Nevitt 2017a; Tudur Smith 2007).
O B J E C T I V E S
To review the time to treatment failure, remission and first seizure
with topiramate compared with carbamazepine when used as
monotherapy in people with focal onset seizures (simple or com-
plex focal and secondarily generalised), or generalised onset tonic-
clonic seizures (with or without other generalised seizure types).
M E T H O D S
Criteria for considering studies for this review
Types of studies
• Randomised controlled trials (RCTs) using either an
adequate method of allocation concealment (e.g. sealed opaque
envelopes) or a quasi-randomised method of allocation (e.g.
allocation by date of birth)
• Trials may have been double-blind, single-blind, or
unblinded
• Trials must be of parallel design; cross-over studies are not
an appropriate design for measuring the long-term outcomes of
interest in this review (see Types of outcome measures)
• Trials must include a comparison of topiramate
monotherapy with carbamazepine monotherapy in individuals
with epilepsy; therefore, cluster-randomised studies are not an
eligible design
Types of participants
• We included children or adults with focal onset seizures
(simple focal, complex focal or secondarily generalised tonic-
clonic seizures), or generalised onset tonic-clonic seizures (with
or without other generalised seizure types, i.e. those who had
only generalised tonic-clonic seizures and those who had both
generalised onset tonic-clonic seizures and generalised seizures of
other types, e.g. absence, myoclonic etc.)
• We excluded individuals with other generalised seizure
types alone without generalised tonic-clonic seizures (e.g. those
who had only absence seizures without any generalised tonic-
clonic seizures), due to differences in first-line treatment
guidelines for other generalised seizure types ( NICE 2012).
• We included individuals who had a new diagnosis of
epilepsy or who had experienced a relapse following antiepileptic
monotherapy withdrawal only, due to differences in first-line
treatment guidelines for individuals with refractory epilepsy (
NICE 2012).
Types of interventions
Included studies had to have made a randomised comparison of
topiramate and carbamazepine (of any dose) as monotherapy. If
studies included additional arms of treatments, other than topira-
mate and carbamazepine, we did not include these treatment arms
in our analysis of the review.
Types of outcome measures
Below is a list of outcomeswe investigated in this review. Reporting
of these outcomes in the original study report was not an eligibility
requirement for this review.
Primary outcomes
Time to treatment failure (retention time). This was a combined
outcome reflecting both efficacy and tolerability, as the following
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may have led to failure of treatment: continued seizures, side ef-
fects, non-compliance or the initiation of additional add-on treat-
ment. This is an outcome to which the participant makes a contri-
bution and is the primary outcome measure recommended by the
Commission on Antiepileptic Drugs of the International League
Against Epilepsy (ILAE 1998; ILAE 2006).
Time to treatment failure is considered according to the following
three definitions.
• Time to treatment failure for any treatment-related reason
(continued seizures, side effects, non-compliance or the
initiation of additional add-on treatment)
• Time to treatment failure due to adverse events (i.e. side
effects)
• Time to treatment failure due to lack of efficacy (i.e.
continued seizures)
Secondary outcomes
• Time to first seizure recurrence post-randomisation
• Time to achieve six-month remission (seizure-free period)
post-randomisation
• Time to achieve 12-month remission (seizure-free period)
post-randomisation
• Incidence of adverse events (all reported, whether related or
unrelated to treatment) and adverse events leading to treatment
withdrawal
Search methods for identification of studies
Electronic searches
We ran searches for the original review on 14 April 2016, and
subsequent searches on 22 May 2018. For the latest update we
searched the following databases.
• Cochrane Register of Studies (CRS Web, 22 May 2018)
using the search strategy shown in Appendix 1. This includes the
Cochrane Epilepsy Group Specialized Register and the Cochrane
Central Register of Controlled Trials (CENTRAL).
• MEDLINE (Ovid, 1946 to 22 May 2018) using the search
strategy shown in Appendix 2.
• ClinicalTrials.gov (22 May 2018) using the search strategy
shown in Appendix 3.
• WHO International Clinical Trials Registry Platform
(ICTRP, 22 May 2018) using the search strategy shown in
Appendix 4.
Searching other resources
We handsearched the reference lists of retrieved studies for addi-
tional reports of relevant studies. We contacted Novartis (formerly
Ciba Geigy, manufacturers of carbamazepine), Janssen Pharma-
ceuticals (manufacturers of topiramate) and the original investi-
gators of relevant trials to identify any additional published or un-
published data.
Data collection and analysis
Selection of studies
Two review authors (SJN, AGM) independently assessed studies
for inclusion, resolving any disagreements by discussion.
Data extraction and management
We requested the following IPD for all studies meeting our inclu-
sion criteria.
• Trial design and methods
◦ Method of generation of random list
◦ Method of allocation concealment
◦ Stratification factors
◦ Blinding methods
• Participant covariates
◦ Sex
◦ Age
◦ Seizure types
◦ Time between first seizure and randomisation
◦ Number of seizures prior to randomisation (with
dates)
◦ Presence of neurological signs
◦ Electroencephalographic (EEG) results
◦ Computerised tomography/magnetic resonance
imaging (CT/MRI) results
• Follow-up data
◦ Treatment allocation
◦ Date of randomisation
◦ Dates of follow-up
◦ Dates of seizures post-randomisation or seizure
frequency data between follow-up visits
◦ Dates of treatment withdrawal or failure and reasons
for treatment withdrawal or failure
◦ Dose
◦ Dates of dose changes
If IPD were not available for a trial, we intended to carry out an
assessment to see whether the trial reported any relevant aggregate
level data or whether we could indirectly estimate such data us-
ing the methods of Parmar 1998 and Williamson 2002. Where
graphical time-to-event data (e.g. Kaplan-Meier curves) were pub-
lished, with or without corresponding effective numbers at risk,
we intended to use a macro-enabled Microsoft Excel spreadsheet
to indirectly estimate hazard ratios (HRs) or make use of graphical
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digitising software, if appropriate, and the quality of the published
graph(s) allowed (Excel 2010; Tierney 2007).
We accepted follow-up and outcome data in any format provided.
One trial provided dates of seizures after randomisation (Privitera
2003), and one study provided the number of seizures recorded at
each follow-up visit (SANADA2007). To enable the calculationof
time-to-event outcomes for studies that provided seizure data only
in terms of the number of seizures recorded between each follow-
up visit, rather than the specific dates of seizures, we applied linear
interpolation to approximate dates of seizures between follow-up
visits. For example, if the trial recorded four seizures between two
visits that occurred on 1 March 2010 and 1 May 2010 (interval
of 61 days), then we estimated that the first seizure took place
around 13March 2010. This method allowed the computation of
an estimate of the time to six- and 12-month remission for studies
of sufficient length.
We calculated time to first seizure from the date of randomisation
to the date that we estimated the first seizure to have occurred. If
seizure data were missing for a particular visit, we censored these
outcomes at the previous visit. We also censored these outcomes if
the individual died or if follow-up ceased prior to the occurrence
of the event of interest.
We calculated time to six- and 12-month remission from the date
of randomisation to the date (or estimated date) that the individ-
ual had first been free of seizures for six or 12 months, respectively
(e.g. 365 days for those who achieve 12-month remission imme-
diately). If the person had one or more seizure(s) during the trial,
a six- or 12-month seizure-free period could also occur between
the estimated date of the last seizure during the trial and a period
of six or 12 months of seizure freedom.
We calculated time to treatment failure as the date of randomisa-
tion to the date of withdrawal from the trial or treatment failure.
For the time-to-event analysis, we defined an ’event’ as the failure
or withdrawal of the allocated treatment because of reasons related
to the treatment (i.e. lack of efficacy, occurrence of adverse events,
or both; non-compliance with the treatment regimen; withdrawal
of consent from the trial; etc). We censored the outcome if treat-
ment was withdrawn for reasons not related to the trial treatment
(i.e. loss to follow-up, death that was not treatment- or epilepsy-
related, etc). We also censored individuals who were still on allo-
cated treatment at the date of the end of follow-up.
We considered documented reasons for withdrawal or treatment
failure on a case-by-case basis for relation to treatment; two au-
thors (SJN, MS) independently classified reasons for failures as
events or censored, and resolved any disagreements by discussion.
If included trials classified the reasons for withdrawal or failure as
events or censored differently from our definitions, we conducted
sensitivity analyses to account for differences in the definition of
a treatment failure ’event’.
Assessment of risk of bias in included studies
Two review authors (SJN,MS) independently assessed all included
trials for risk of bias according to the Cochrane ’Risk of bias’ tool
(Higgins 2017), resolving any disagreements by discussion. We
rated each of the following six domains as low, unclear or high risk
of bias: method of generating random sequence, allocation con-
cealment, blinding methods, incomplete outcome data, selective
outcome reporting, and other sources of bias. Any discrepancies
in the two authors’ ’Risk of bias’ judgements were resolved by dis-
cussion.
In the event of the presence of a high risk of bias in included trials
(due to inadequate allocation concealment or lack of blinding),
we intended to conduct sensitivity analyses excluding these trials.
Measures of treatment effect
We measured all outcomes in this review as time-to-event out-
comes using the HR as the measure of treatment effect. We cal-
culated 95% confidence intervals (CIs) to provide a measure of
precision of the treatment effect estimate. We calculated all out-
comes from IPD provided, where possible, and if IPD were not
available, we intended to use extracted or estimated aggregate data
from published trials if possible.
We considered adverse events narratively rather than formally in
analyses due to anticipated differences in the format of adverse
event reporting in the included studies.
Unit of analysis issues
Cross-over and cluster-randomised studies were not an eligible
design for this review (see Types of studies).
If eligible studies included multiple treatment arms of different
topiramate or carbamazepine doses, we pooled study arms of the
same treatment in primary analyses to allow a comparison of top-
iramate and carbamazepine. For one trial, which randomised par-
ticipants to two doses of topiramate (100 mg/day or 200 mg/day),
we performed a secondary analysis to analyse the different doses
compared with carbamazepine (Privitera 2003).
It was not within the scope of this review to compare directly dif-
ferent doses of the same treatment (e.g. the two doses of topira-
mate).
Dealing with missing data
For each trial that supplied IPD, we performed the following con-
sistency checks.
• We cross-checked study details against any published report
of the study and contacted the data providers if we found
missing data, errors or inconsistencies.
• If the data providers could not resolve inconsistencies
between IPD and published data, we intended to either perform
sensitivity analyses or exclude the data from the meta-analysis,
depending on the extent of the inconsistencies.
• If possible, we reviewed the chronological randomisation
sequence and checked the balance of prognostic factors, taking
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account of any stratification factors in the randomisation
procedure.
Assessment of heterogeneity
We assessed heterogeneity statistically using the Q test (P < 0.10
for significance) and the I2 statistic (values greater than 50% in-
dicating considerable heterogeneity, Higgins 2003), with output
produced using the generic inverse variance approach available in
Review Manager (Review Manager 2014). We also assessed het-
erogeneity visually by inspecting forest plots.
Assessment of reporting biases
Two review authors (SJN,MS) undertook full quality and ’Risk of
bias’ assessments according to methods outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2017).
In theory, a review using IPD should overcome issues of reporting
biases, as unpublished data can be provided and unpublished out-
comes calculated. We requested all study protocols with IPD. If
we suspected any selective reporting bias, we intended to explore
the extent of the bias using the Outcome Reporting Bias In Trials
(ORBIT) classification system (Kirkham 2010).
Data synthesis
We carried out our analysis on an intention-to-treat basis (that
is, we analysed participants in the group to which they were ran-
domised, irrespective of which treatment they actually received).
Therefore, for the time-to-event outcomes ’time to six-month re-
mission’, ’time to 12-month remission’, and ’time to first seizure
post-randomisation’, we did not censor participants if treatment
was withdrawn or failed. Intention-to-treat analyses often tend to
suggest equivalence between treatments (i.e. no statistically signif-
icant difference), so we intended to undertake a secondary per-
protocol analysis as a sensitivity analysis if the primary analyses
suggest equivalence. In this case, participants would be censored
at the time of treatment failure for seizure outcomes.
For all outcomes, we investigated the relationship between the
time-to-event and treatment effect of the AEDs. We used Cox
proportional hazards regression models to obtain trial-specific es-
timates of log (HR), or treatment effect and associated standard
errors in Stata Statistical Software, version 14 (Stata 2015). The
model assumes that the ratio of hazards (risks), between the two
treatment groups is constant over time (i.e. hazards are propor-
tional). We tested this proportional hazards assumption of the
Cox regression model for each outcome of each trial by testing the
statistical significance of a time-varying covariate in the model.
We evaluated overall estimates of HRs (with 95% CIs), using the
generic inverse variance method in MetaView. We expressed re-
sults as a HR and a 95% CI. We used a fixed-effect model and,
if considerable heterogeneity was present (I2 statistic > 50%), we
intended to repeat the analysis using a random-effects model.
By convention, a HR greater than 1 indicated that an event was
more likely to occur earlier with topiramate than with carba-
mazepine. Hence, for time to treatment failure or time to first
seizure, a HR greater than 1 indicates a clinical advantage for car-
bamazepine (e.g. a HR of 1.2 would suggest a 20% increase in
risk of treatment failure from topiramate compared with carba-
mazepine), and for time to six-month, 12-month and 24-month
remission, a HR greater than 1 indicates a clinical advantage for
topiramate (i.e. the seizure-free period occurs earlier with topira-
mate than with carbamazepine).
Subgroup analysis and investigation of heterogeneity
Due to the strong clinical belief that some AEDs are more effec-
tive for some seizure types than for others (see Description of the
intervention and How the intervention might work), we intended
to stratify all analyses by epilepsy type (focal onset versus gener-
alised onset), according to the classification of main seizure type at
baseline. We classified focal seizures (simple or complex) and fo-
cal secondarily generalised seizures as focal epilepsy. We classified
primarily generalised tonic-clonic seizures (with or without other
seizure types), as generalised epilepsy.
Seizure type was missing (unclassified) for 89 participants from
SANADA 2007 and 13 participants were classified as having gen-
eralised onset seizures, even though the trial was designed to in-
clude only participants with focal onset seizures. Also, only 88
participants from Privitera 2003 were classified as having gener-
alised onset seizures (by design the majority of participants form-
ing the comparison of carbamazepine and topiramate had focal
onset seizures, see Characteristics of included studies for more de-
tails) and seizure type wasmissing (unclassified) for 22 participants
from Privitera 2003.
Therefore, for the purposes of subgroup analysis, we felt it would
be more appropriate to compare the subgroup of participants with
focal onset epilepsy and the subgroup with ’generalised onset or
unclassified epilepsy’. We conducted a Chi2 test of interaction
between treatment and epilepsy type.
If further trials recruiting individuals with generalised seizure types
are included in updates of this review, we hope to perform a sub-
group analysis of focal onset versus generalised onset epilepsy.
If we deemed considerable statistical heterogeneity to be present
(I2 statistic > 50%), we intended to perform meta-analyses using
a random-effects model in addition to a fixed-effect model and
present the results of both models. Also, if possible, we considered
investigating factors that could contribute to heterogeneity (e.g.
participant covariates, trial design as described in Data extraction
and management) via further subgroup analyses or via meta-re-
gression models.
Sensitivity analysis
We intended to perform sensitivity analyses if we considered stud-
ies to be at high risk of bias (see Assessment of risk of bias in
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included studies), if we found inconsistencies between published
study reports and the IPD provided (see Dealing with missing
data) or if trials included multiple treatment arms (see Unit of
analysis issues). We also intended to perform several sensitivity
analyses to test the robustness of our results in relation to the char-
acteristics of the included trials.
• Definition of time to treatment failure: we classified reasons
for treatment failure or withdrawal that were related to the trial
treatment as ’events’ and reasons not related to treatment as
’censored’ in analyses of ’time to treatment failure.’ If included
trials classified the reasons for withdrawal or failure as events or
censored differently from us, we conducted sensitivity analyses to
account for differences in the definition of a withdrawal or
failure ’event’ (SANAD A 2007).
• Aggregate data: this is an IPD review; we will include IPD
only in all primary analyses. We were unable to extract any
aggregate data from the one trial included in this review for
which no IPD were available (Resendiz-Aparicio 2004), but if we
are able to extract aggregate data from trials included in future
updates of this review (see Data extraction and management), we
intend to combine aggregate data with IPD in sensitivity
analyses and examine the differences between the IPD and
combined analyses.
• Open-label extension: one included trial comprised a six-
month, double-blind phase followed by an open-label extension
phase (Privitera 2003). As both blinded and open-label trials are
eligible for inclusion in this review, by our intention-to-treat
approach, we included the entire follow-up period in analysis.
We also performed a sensitivity analysis of outcomes of time to
treatment failure, time to first seizure and time to six-month
remission, censoring these outcomes at the end of the double-
blind phase and comparing results to those from the primary
analysis (we note that in this analysis, time to six-month
remission becomes time to immediate six-month remission when
considered over a six-month period).
• Misclassification of seizure type: this is a recognised
problem in epilepsy, whereby some people with generalised
seizures have been mistakenly classed as having focal onset
seizures and vice versa. Such misclassification had an impact on
the results of three reviews in a series of pair-wise reviews of
monotherapy in epilepsy comparing carbamazepine,
phenobarbitone, phenytoin and sodium valproate, in which
around 30% to 50% of participants analysed may have had their
seizure type misclassified as generalised onset (Nevitt 2017b;
Nevitt 2018b; Nevitt 2018d). Given the potential biases
introduced into these three reviews, we examined the
distribution of age at onset for individuals with generalised
seizures in the trials included in this review, to assess the potential
impact of misclassification of seizure type on the outcomes.
(There is clinical evidence that individuals with generalised onset
seizures are unlikely to have an ’age of onset’ greater than 25 to
30 years (Malafosse 1994)). Given that most of the individuals
recruited to the trials included in the present review experienced
focal onset seizures, this sensitivity analysis was not appropriate
for this review and instead we performed a subgroup analysis of
focal onset versus generalised onset or unclassified epilepsy (see
Subgroup analysis and investigation of heterogeneity).
For updates of the review, if future trials recruit more individuals
with generalised onset seizures, we intend to perform a sensitivity
analysis in two ways:
• we will reclassify individuals with generalised seizure types
and age at onset greater than 30 years as having focal onset
seizures, and we will repeat subgroup analyses;
• we will reclassify individuals with generalised seizure types
and age at onset greater than 30 years into an ’uncertain seizure
type’ group, and we will repeat subgroup analyses with three
groups.
’Summary of findings’ table
We have presented two ’Summary of findings’ tables (Summary of
findings for the main comparison; Summary of findings 2). The
first presents the summary of the main comparison reporting the
primary outcome of ’time to treatment failure’ in the subgroups of
participants with focal onset epilepsy and generalised onset or un-
classified epilepsy overall for all participants, adjusted by epilepsy
type.
The second ’Summary of findings’ table reports the secondary out-
comes of ’time to first seizure’ and ’time to 12-month remission’
in the subgroups of participants with focal onset epilepsy and gen-
eralised onset or unclassified epilepsy overall for all participants,
adjusted by epilepsy type.
We determined the certainty of the evidence using the GRADE
approach (Hultcrantz 2017; GRADEPro GDT 2015), whereby
we downgraded evidence in the presence of a high risk of bias in
at least one trial, indirectness of the evidence, unexplained hetero-
geneity or inconsistency, imprecision of results or high probability
of publication bias. We downgraded evidence by one level if we
considered the limitation to be serious and two levels if we con-
sidered it to be very serious.
R E S U L T S
Description of studies
Results of the search
We identified 136 records from the databases and search strategies
outlined in Electronic searches.We found no additional records by
handsearching and checking the reference lists of included studies.
We removed 30 duplicate records and screened 106 records (title
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and abstract) for inclusion in the review. We excluded 85 records
based on title and abstract, and assessed 16 records describing four
full-text articles for inclusion in the review. We excluded three
records linked to a single study from the review (see Excluded
studies below) and included three studies in the review described
in 13 records (see Included studies below). See Figure 1 for a
PRISMA study flow diagram.
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Figure 1. Study flow diagram.
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Included studies
We included three studies in the review (Privitera 2003; Resendiz-
Aparicio 2004; SANAD A 2007).
One trial recruited individuals over the age of six years (Privitera
2003), and another trial recruited individuals over the age of four
years (SANADA2007). The third trial recruited children between
the ages of six and 18 years (Resendiz-Aparicio 2004).
One trial recruited individuals with focal seizures (with or with-
out secondary generalisation) (Resendiz-Aparicio 2004). SANAD
A 2007 was designed to recruit individuals with focal seizures
only, but some individuals with generalised onset or unclassi-
fied seizures were recruited; we examine this seizure classification
in subgroup analysis. Privitera 2003 was designed in two strata,
based on whether the recommended treatment would be carba-
mazepine or sodium valproate. Within the two strata, partici-
pants were randomised to topiramate 100 mg/day or 200 mg/day,
or carbamazepine/sodium valproate depending on the stratum.
Only the carbamazepine stratum (participants randomised to car-
bamazepine or one of the two doses of topiramate) was eligible for
the randomised comparison in this review. The majority of partic-
ipants within this stratum had focal seizures but some individuals
with generalised onset or unclassified seizures were also recruited;
we examine this seizure classification in subgroup analysis.
Two trials recruited individuals with new-onset seizures (Privitera
2003; Resendiz-Aparicio 2004), and one trial recruited individ-
uals with new-onset, relapsed or recurrent seizures (failure of an
antiepileptic drug (AED) not randomised in the trial) (SANAD
A 2007).
All three trials were conducted in a multicentre setting; Resendiz-
Aparicio 2004 was conducted in Mexico, SANAD A 2007 was
conducted in the UK and Privitera 2003 was conducted in centres
across the USA, Canada, Europe and South America.
Individual participant data (IPD) were available for two trials
randomising 1151 participants to carbamazepine or topiramate
(Privitera 2003; SANAD A 2007). For the third trial, which
recruited 88 participants, we were unable to contact the orig-
inal authors and so IPD could not be included in this review
(Resendiz-Aparicio 2004). Overall, IPD were available for 93% of
the total eligible 1239 participants.
Data were available for the following participant characteristics
(percentage of 1151 participants with data available): drug ran-
domised (100%), sex (98%, data missing for 18 participants in
SANAD A 2007), age at randomisation (98%, data missing for
18 participants in SANAD A 2007), number of seizures in six
months prior to randomisation (98%, missing for 21 participants
in SANAD A 2007) and seizure type (90%, data missing for 22
participants in Privitera 2003 and 89 participants in SANAD A
2007).
Results of neurological examinations were available for 738 of 756
participants (98%) from SANADA 2007 (data for 18 participants
missing). This information was not available for Privitera 2003.
No information was available from either trial regarding elec-
troencephalographic (EEG) or computerised tomography/mag-
netic resonance imaging (CT/MRI) results and time since first
seizure to randomisation.
See the Characteristics of included studies and Table 1 for further
details.
Excluded studies
We excluded one study described in three records (Kang 2007).
This study recruited children with only benign rolandic epilepsy,
which was an ineligible seizure type for this review.
Risk of bias in included studies
For further details, see the Characteristics of included studies and
Figure 2.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
As all three trials described adequate methods of generation of a
random list we judged them to be at low risk of bias; Privitera
2003 used computer-generated block randomisation, Resendiz-
Aparicio 2004 used random number tables and SANAD A 2007
used minimisation.
SANAD A 2007 used telephone randomisation to a central al-
location service, and so we judged the study to be at low risk of
bias for allocation concealment. As the other two trials did not
describe a method of allocation concealment we judged them to
be at unclear risk of bias.
Blinding
We judged the two open-label trials to be at high risk of perfor-
mance and detection bias (Resendiz-Aparicio 2004; SANAD A
2007). The third trial comprised a six-month double-blind phase
followed by an open-label extension phase; it was unclear if out-
come assessors were blinded in this trial.
Incomplete outcome data
In theory, a review using IPD should overcome issues of attrition
bias as unpublished data can be provided, unpublished outcomes
calculated, and all randomised participants can be analysed by
an intention-to-treat approach. Both trials providing IPD for all
randomised individuals reported the extent of follow-up for each
individual (Privitera 2003; SANAD A 2007). We queried any
missing data with the original trial authors. From the information
provided by the authors, we deemed the small amount of missing
data present (see Included studies) to be missing at random and
considered that it did not affect our analysis.
For the trial for which no IPD were provided, we included only
those participants who completed the trial in analyses; this is not
an intention-to-treat approach so we judged this trial to be at high
risk of attrition bias (Resendiz-Aparicio 2004).
Selective reporting
In theory, a review using IPD should overcome issues of reporting
biases as unpublished data can be provided and unpublished out-
comes calculated. We requested trial protocols in all IPD requests
and protocols were provided for Privitera 2003 and SANAD A
2007. We received sufficient IPD to calculate all outcomes for
both trials.
For the trial for which no IPD were provided, no protocol was
available and the trial publication was translated from Spanish by
SJN. We judged seizure outcomes and adverse events to be well
reported and to be at low risk of selective reporting bias (Resendiz-
Aparicio 2004).
Other potential sources of bias
We identified no other potential sources of bias in any of the trials.
Effects of interventions
See: Summary of findings for the main comparisonTopiramate
compared with carbamazepine for epilepsy (time to treatment
failure); Summary of findings 2 Topiramate compared with
carbamazepine for epilepsy (secondary outcomes)
Table 2 gives details regarding the number of individuals (with
IPD) contributing to each analysis, Summary of findings for the
main comparison summarises the results for the primary outcome
‘time to treatment failure’ and Summary of findings 2 summarises
the results for the secondary outcomes ‘time to first seizure’ and
‘time to 12-month remission.’
Survival curve (cumulative incidence) plots are shown in Figure 3,
Figure 4, Figure 5, Figure 6, Figure 7, Figure 8, Figure 9, Figure
10, Figure 11, Figure 12, Figure 13 and Figure 14. We produced
all cumulative incidence plots in Stata software version 14.1. We
used Stata software version 14 to produce all survival curve plots
using data from all trials providing IPD combined (Stata 2015).
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Figure 3. Time to treatment failure - any reason related to the treatment (CBZ: carbamazepine; TPM:
Topiramate)
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Figure 4. Time to treatment failure - any reason related to the treatment, by seizure type (CBZ:
carbamazepine; TPM: Topiramate)
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Figure 5. Time to treatment failure due to adverse events (CBZ: carbamazepine; TPM: Topiramate)
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Figure 6. Time to treatment failure due to adverse events, by seizure type (CBZ: carbamazepine; TPM:
Topiramate)
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Figure 7. Time to treatment failure due to lack of efficacy (CBZ: carbamazepine; TPM: Topiramate)
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Figure 8. Time to treatment failure due to lack of efficacy, by seizure type (CBZ: carbamazepine; TPM:
Topiramate)
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Figure 9. Time to first seizure after randomisation (CBZ: carbamazepine; TPM: Topiramate)
24Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 10. Time to first seizure after randomisation, by seizure type (CBZ: carbamazepine; TPM:
Topiramate)
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Figure 11. Time to 12-month remission (CBZ: carbamazepine; TPM: Topiramate)
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Figure 12. Time to 12-month remission by seizure type (CBZ: carbamazepine; TPM: Topiramate)
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Figure 13. Time to 6-month remission (CBZ: carbamazepine; TPM: Topiramate)
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Figure 14. Time to 6-month remission by seizure type (CBZ: carbamazepine; TPM: Topiramate)
We note that participants with event times of zero (i.e. those who
experienced treatment failure or experienced seizure recurrence on
the day of randomisation), are not included in the ’numbers at
risk’ on the graphs and that data are not stratified by trial within
these survival curve plots. All figures are intended to provide a
visual representation of outcomes, extent of follow-up and visual
differences between seizure types. These graphs are not intended to
show statistical significance and numerical values may vary com-
pared to the text due to differences in methodology.
We calculated all the hazard ratios (HRs) presented using generic
inverse variance fixed-effect meta-analysis unless otherwise stated.
All analyses met the assumption of proportional hazards (addition
of time varying covariate into the model non-significant) unless
stated.
Primary outcome
Time to treatment failure (retention time)
For this outcome, a HR less than 1 indicates a clinical advantage
for topiramate.
Table 3 shows the reasons for premature termination for 1151
participants in the two trials included in this analysis and how
we classified these treatment failures or withdrawals in analysis of
IPD. Times to treatment failure were available for 1129 partici-
pants in the two trials (98% of total 1151 participants included
in analysis). Withdrawal times were missing for 22 participants
in SANAD A 2007 (see Table 2); however, as all 22 participants
withdrew for reasons which would have been censored in analysis,
we consider the impact of these missing participants on the anal-
ysis to be negligible.
Of 1151 participants, 670 (58%) prematurely withdrew from
treatment: 377 of 644 (59%) participants randomised to topira-
mate and 293 of 507 (58%) participants randomised to carba-
mazepine. We deemed 553 participants (83% of total treatment
failures) to have failed treatment for reasons related to the allo-
cated drug and classified these reasons as ’events’ in analysis - 322
randomised to topiramate (85% of topiramate treatment failures)
and 231 randomised to carbamazepine (79% of carbamazepine
treatment failures). The most common treatment-related reason
for treatment failure was adverse events: 44% of total treatment
failures, 159 participants randomised to topiramate (42% of total
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topiramate treatment failures) and 136 participants randomised to
carbamazepine (46% of total carbamazepine treatment failures).
We classed the other 117 treatment failures or withdrawals (55
participants randomised to topiramate and 62 randomised to car-
bamazepine) to be not related to the allocated drug and censored
these participants in analysis, in addition to the 481 participants
(267 receiving topiramate and 214 receiving carbamazepine) who
completed the trial without failing or withdrawing from the treat-
ment.
Considering ’time to treatment failure for any reason related to
the treatment’, the overall pooled HR (for 1129 participants pro-
viding IPD from 2 trials) was 1.15 (95% confidence interval (CI)
0.97 to 1.37; P = 0.11, moderate-certainty evidence; Analysis 1.1),
indicating a potential advantage to carbamazepine that was not
statistically significant; in other words, treatment failure may oc-
cur earlier on topiramate than carbamazepine but we cannot rule
out a slight advantage to topiramate or no difference between the
drugs. No heterogeneity was present between trials (I2 = 0%).
Considering ’time to treatment failure due to adverse events’ (all
other reasons for treatment failure or treatment withdrawal cen-
sored in analysis), the overall pooled HR (for 1129 participants
providing IPD from 2 trials) was 1.01, 95% CI 0.82 to 1.26; P
= 0.90, moderate-certainty evidence; Analysis 1.2), indicating no
clear differences between the drugs. No important heterogeneity
was present between trials (I2 = 15%).
Considering ’time to treatment failure due to lack of efficacy’ (all
other reasons for treatment failure or treatment withdrawal cen-
sored in analysis), the overall pooled HR (for 1129 participants
providing IPD from 2 trials) was 1.45, 95% CI 1.08 to 1.96; P =
0.01, moderate-certainty evidence; Analysis 1.3), indicating a sta-
tistically significant advantage to carbamazepine; in other words,
treatment failure due to adverse events occurred earlier on topira-
mate than carbamazepine in the two included trials. No hetero-
geneity was present between trials (I2 = 0%).
Subgroup analyses: seizure type (focal onset versus
generalised onset or unclassified epilepsy)
See Subgroup analysis and investigation of heterogeneity for more
details regarding the definitions of subgroups.
Considering time to treatment failure for any reason related to the
treatment, for participants with focal onset seizures (937 partici-
pants providing IPD), the pooled HR was 1.21 (95% CI 1.01 to
1.46; P =0.04,moderate-certainty evidence; Analysis 1.4), indicat-
ing a statistically significant advantage for carbamazepine; in other
words, treatment failure due to adverse events occurred earlier on
topiramate than carbamazepine in the two included trials. For par-
ticipants with generalised onset or unclassified epilepsy (192 par-
ticipants providing IPD), the pooled HR was 0.88 (95% CI 0.56
to 1.39; P = 0.59, low-certainty evidence; Analysis 1.4), indicating
that treatment failure may occur earlier on carbamazepine than
topiramate but CIs are wide so we cannot rule out an advantage
to carbamazepine or no differences between the drugs.
The overall pooledHR (adjusted for epilepsy type for 1129 partic-
ipants) was HR 1.16 (95% CI 0.97 to 1.38, P = 0.10, moderate-
certainty evidence, Analysis 1.4), indicating (as above) a potential
advantage to carbamazepine that is not statistically significant. No
between-trial heterogeneity was present overall or by subgroup (I
2 = 0%) and there was no evidence of a difference between the
subgroups (test for subgroup differences P = 0.21; Analysis 1.4).
Considering ’time to treatment failure due to adverse events’ (all
other reasons for treatment failure or treatment withdrawal cen-
sored in analysis), for participants with focal onset seizures (937
participants providing IPD), the pooled HR was 1.08 (95% CI
0.85 to 1.36; P = 0.53, moderate-certainty evidence; Analysis 1.5),
indicating no clear differences between the drugs. For participants
with generalised onset or unclassified epilepsy (192 participants
providing IPD), the pooled HR was 0.72 (95% CI 0.39 to 1.31;
P = 0.28, low-certainty evidence; Analysis 1.5), indicating that
treatment failure may occur earlier on carbamazepine than topi-
ramate but CIs are wide so we cannot rule out an advantage to
carbamazepine or no differences between the drugs.
The overall pooledHR (adjusted for epilepsy type for 1129 partic-
ipants) was HR 1.02 (95% CI 0.82 to 1.27; P = 0.84, moderate-
certainty evidence; Analysis 1.5), indicating no clear differences
between the drugs. No between-trial heterogeneity was present
overall or by subgroup (I2 = 0%) and there was no evidence of a
difference between the subgroups (test for subgroup differences P
= 0.22; Analysis 1.5).
Considering ’time to treatment failure due to lack of efficacy’ (all
other reasons for treatment failure or treatment withdrawal cen-
sored in analysis), for participants with focal onset seizures (937
participants providing IPD), the pooled HR was 1.47 (95% CI
1.07 to 2.02; P = 0.02, moderate-certainty evidence; Analysis 1.6),
indicating a statistically significant advantage to carbamazepine;
in other words, for individuals with focal onset seizures, treatment
failure due to adverse events occurred earlier on topiramate than
carbamazepine in the two included trials. For participants with
generalised onset or unclassified epilepsy (192 participants pro-
viding IPD), the pooled HR was 1.41 (95% CI 0.54 to 3.67; P =
0.48, low-certainty evidence; Analysis 1.6), indicating that treat-
ment failure may occur earlier on topiramate than carbamazepine
but CIs are wide so we cannot rule out an advantage to topiramate
or no differences between the drugs.
The overall pooled HR (adjusted for epilepsy type for 1129 par-
ticipants) was HR 1.46 (95% CI 1.08 to 1.98; P = 0.01, moder-
ate-certainty evidence; Analysis 1.6), indicating a statistically sig-
nificant advantage to carbamazepine; in other words, treatment
failure due to adverse events occurred earlier on topiramate than
carbamazepine in the two included trials. No between-trial het-
erogeneity was present overall or by subgroup (I2 = 0%) and there
was no evidence of a difference between the subgroups (test for
subgroup differences P = 0.94; Analysis 1.6).
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Sensitivity analysis
We performed a sensitivity analysis including only IPD from only
the six-month double-blind period of Privitera 2003; participants
who failed treatment after six months (9 receiving carbamazepine
and 30 receiving topiramate) were censored at six months. When
only treatment from the first six months of Privitera 2003 were
combined with IPD from SANADA 2007, numerical results were
very similar and conclusions were unchanged (results available
from authors on request).
One included trial allocated participants to three treatment arms,
100mg/day topiramate, 200mg/day topiramate or carbamazepine
(Privitera 2003). Table 4 shows sensitivity analysis comparing the
primary analysis (pooled topiramate arms versus carbamazepine),
topiramate 100 mg/day versus carbamazepine and topiramate 200
mg/day versus carbamazepine. Results were similar across all three
analyses and conclusions were unchanged.
The reason for treatment failure ’participant choice’ was classi-
fied as an event in this review but censored in the included trial
(SANADA 2007). This was the primary reason for treatment fail-
ure specified in 14 participants (see Table 3). Sensitivity analysis
classifying this reason as a censored observation for these 14 par-
ticipants did not change our conclusions (results available from
authors on request).
Secondary outcomes
Time to first seizure post-randomisation
For this outcome, a HR less than 1 indicates a clinical advantage
for topiramate.
No seizure recurrence data after randomisation were available for
36 participants in SANAD A 2007, therefore 1115 participants
(97% of total 1151 participants) from the two trials were included
in the analysis of ’time to first seizure after randomisation’.
A total of 720 participants (65% of participants included in anal-
ysis) experienced seizure recurrence, 403 of 624 (65%) receiving
topiramate and 317 of 491 (65%) receiving carbamazepine.
The overall pooledHR (for 1115 participants providing IPD from
two trials) was 1.09 (95%CI 0.94 to 1.27; P = 0.24, high-certainty
evidence; Analysis 1.7), indicating a potential advantage for car-
bamazepine that was not statistically significant; in other words,
seizure recurrence may occur earlier on topiramate than carba-
mazepine but we cannot rule out a slight advantage to topiramate
or no difference between the drugs. No important heterogeneity
was present between trials (I2 = 39%).
Subgroup analyses: seizure type (focal onset versus
generalised onset or unclassified epilepsy)
See Subgroup analysis and investigation of heterogeneity for more
details regarding the definitions of subgroups.
For participants with focal onset seizures (925 participants pro-
viding IPD), the pooled HR was 1.12 (95% CI 0.95 to 1.29; P
= 0.17, high-certainty evidence; Analysis 1.8) and for participants
with generalised onset or unclassified epilepsy (190 participants
providing IPD), the pooled HR was 1.08 (95% CI 0.70 to 1.66;
P = 0.73, moderate-certainty evidence; Analysis 1.8), both indi-
cating a potential advantage to carbamazepine that was not statis-
tically significant.
There was no evidence of a difference between the subgroups (test
for subgroup differences P = 0.89; Analysis 1.8). There was some
heterogeneity between the two trials in the subgroup of generalised
onset or unclassified epilepsy (I2 = 61%), which is likely due to
the variability in the ’unclassifiable’ nature of the epilepsy in many
of the participants in this subgroup (i.e. the subgroup is likely to
be comprised of some individuals experiencing focal epilepsy and
others experiencing generalised epilepsy). No heterogeneity was
present in the subgroup of participants classified as having focal
epilepsy (I2 = 0%).
The overall pooled HR (adjusted for epilepsy type for 1115 par-
ticipants) was HR 1.11 (95% CI 0.96 to 1.29; P = 0.17, high-
certainty evidence; Analysis 1.8), indicating an advantage for car-
bamazepine that was not statistically significant.
Sensitivity analysis
We performed a sensitivity analysis including only IPD from the
six-month double-blind period of Privitera 2003; participants who
experienced a first seizure recurrence after six months (8 receiving
carbamazepine and 11 receiving topiramate) were censored at six
months. When only seizure recurrences from the first six months
of Privitera 2003 were combined with IPD from SANADA 2007,
the numerical results were very similar and our conclusions were
unchanged (results available from authors on request).
One included trial allocated participants to three treatment arms,
100mg/day topiramate, 200mg/day topiramate or carbamazepine
(Privitera 2003). Table 4 shows sensitivity analysis comparing the
primary analysis (pooled topiramate arms versus carbamazepine),
topiramate 100 mg/day versus carbamazepine and topiramate 200
mg/day versus carbamazepine. Results were similar across all three
analyses and conclusions were unchanged.
Time to 12-month remission of seizures
For this outcome, a HR less than 1 indicates a clinical advantage
for carbamazepine.
No seizure recurrence data after randomisation were available for
36 participants in SANAD A 2007, therefore 1115 participants
(97% of total 1151 participants) from the two trials were included
in the analysis of time to 12-month remission.
A total of 558 participants (50% of participants included in anal-
ysis) achieved 12-month remission; 277 of 624 (44%) receiving
topiramate and 281 of 491 (57%) receiving carbamazepine.
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Of these 558 participants, 301 achieved immediate remission
(54%), i.e. no seizure recurrence in the immediate 12 months fol-
lowing randomisation; 151 received topiramate and 150 received
carbamazepine.
The overall pooledHR (for 1115 participants providing IPD from
2 trials) was 0.85 (95% CI 0.72 to 1.01; P = 0.07, high-certainty
evidence; Analysis 1.9), indicating a potential advantage for car-
bamazepine that was not statistically significant; in other words,
a seizure-free period of 12 months may occur earlier on carba-
mazepine than topiramate but we cannot rule out a slight advan-
tage to topiramate or no difference between the drugs. No hetero-
geneity was present between trials (I2 = 0%).
Subgroup analyses: seizure type (focal onset versus
generalised onset or unclassified epilepsy)
See Subgroup analysis and investigation of heterogeneity for more
details regarding the definition of subgroups.
For participants with focal onset seizures (925 participants provid-
ing IPD), the pooledHRwas 0.82 (95%CI 0.69 to 0.99; P = 0.04,
high-certainty evidence; Analysis 1.10), indicating a statistically
significant advantage for carbamazepine; in other words, for indi-
viduals with focal onset seizures, a seizure-free period of 12months
occurs significantly earlier on carbamazepine compared to topira-
mate in the two included trials. For participants with generalised
onset or unclassified epilepsy (190 participants providing IPD),
the pooled HR was 0.92 (95% CI 0.61 to 1.41; P = 0.71, mod-
erate-certainty evidence; Analysis 1.10), indicating that a seizure-
free period of 12 months may occur earlier on carbamazepine but
CIs are wide so we cannot rule out an advantage to topiramate or
no differences between the drugs.
The overall pooled HR (adjusted for epilepsy type for 1115 par-
ticipants) was HR 0.84 (95% CI 0.71 to 0.99; P = 0.04, high-
certainty evidence; Analysis 1.10), indicating a statistically signif-
icant advantage for carbamazepine; in other words, a seizure-free
period of 12 months occurs significantly earlier on carbamazepine
compared to topiramate in the two included trials. No important
between-trial heterogeneity was present overall or by subgroup (I
2 < 25% for all analyses) and there was no evidence of a difference
between the subgroups (test for subgroup differences P = 0.63;
Analysis 1.10).
Sensitivity analysis
One included trial allocated participants to three treatment arms,
100mg/day topiramate, 200mg/day topiramate or carbamazepine
(Privitera 2003). Table 4 shows sensitivity analysis comparing the
primary analysis (pooled topiramate arms versus carbamazepine),
topiramate 100 mg/day versus carbamazepine and topiramate 200
mg/day versus carbamazepine. Results were similar across all three
analyses and conclusions were unchanged.
Time to six-month remission of seizures
For this outcome, a HR less than 1 indicates a clinical advantage
for carbamazepine.
No seizure recurrence data after randomisation were available for
36 participants in SANAD A 2007, therefore 1115 participants
(97% of total 1151 participants) from the two trials were included
in the analysis of time to six-month remission.
A total of 790 participants (71% of participants included in anal-
ysis) achieved six-month remission; 422 of 624 (68%) receiving
topiramate and 368 of 491 (75%) receiving carbamazepine.
Of these 790 participants, 441 achieved immediate remission
(56% of participants achieving remission), 240 receiving topira-
mate and 201 receiving carbamazepine.
The overall pooledHR (for 1115 participants providing IPD from
2 trials) was 0.88 (95% CI 0.76 to 1.01; P = 0.09, high-cer-
tainty evidence; Analysis 1.11), indicating an advantage for car-
bamazepine that was not statistically significant; in other words,
a seizure-free period of six months may occur earlier on carba-
mazepine than topiramate but we cannot rule out a slight advan-
tage to topiramate or no difference between the drugs. No hetero-
geneity was present between trials (I2 = 0%).
Subgroup analyses: seizure type (focal onset versus
generalised onset or unclassified epilepsy)
See Subgroup analysis and investigation of heterogeneity for more
details regarding the definitions of subgroups.
For participants with focal onset seizures (925 participants pro-
viding IPD), the pooled HR was 0.86 (95% CI 0.74 to 1.01; P =
0.06, high-certainty evidence; Analysis 1.12) and for participants
with generalised onset or unclassified epilepsy (190 participants
providing IPD), the pooled HR was 0.93 (95% CI 0.66 to 1.30;
P = 0.67, moderate-certainty evidence; Analysis 1.12), both indi-
cating a potential advantage to carbamazepine that was not statis-
tically significant.
The overall pooled HR (adjusted for epilepsy type for 1115 par-
ticipants) was HR 0.87 (95% CI 0.76 to 1.01; P = 0.06, high-cer-
tainty evidence; Analysis 1.12), indicating a potential advantage
for carbamazepine that was not statistically significant; in other
words, a seizure-free period of 12 months may occur earlier on
carbamazepine than topiramate but we cannot rule out a slight
advantage to topiramate or no difference between the drugs. No
important between-trial heterogeneity was present overall or by
subgroup (I2 < 30% for all analyses) and there was no evidence of
a difference between the subgroups (test for subgroup differences
P = 0.69; Analysis 1.12).
Sensitivity analysis
We performed a sensitivity analysis including only IPD from
the six-month double-blind period of Privitera 2003; those who
achieved six months of remission after six months (i.e. those who
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did not experience immediate six-month remission, 11 receiving
carbamazepine and 41 receiving topiramate) were censored at six
months. When only immediate six-month remission data from
Privitera 2003 were combined with IPD from SANAD A 2007,
the pooled HR was 0.86 (0.75 to 1.00, P = 0.05), indicating a
statistically significant advantage for carbamazepine over topira-
mate. We note that this analysis combines immediate six-month
remission in Privitera 2003 with six-month remission at any time
in SANAD A 2007. When analysing only immediate six-month
remission in SANAD A 2007, the pooled HR was 0.88 (0.73 to
1.07, P = 0.19) indicating no significant difference between the
drugs.
One included trial allocated participants to three treatment arms,
100mg/day topiramate, 200mg/day topiramate or carbamazepine
(Privitera 2003). Table 4 shows sensitivity analysis comparing the
primary analysis (pooled topiramate arms versus carbamazepine),
topiramate 100 mg/day versus carbamazepine and topiramate 200
mg/day versus carbamazepine. Results were similar across all three
analyses and conclusions were unchanged.
Incidence of adverse events
Wewere provided with IPD for adverse events experienced during
the trial for two trials (Privitera 2003; SANAD A 2007).
Due to the wide range of events reported in the trials and the
differences in adverse-event profiles of the two drugs, we have
not analysed adverse event data in meta-analysis and provide a
narrative report. This information is summarised in Table 5 and
Table 6. All adverse events are reported according to the definitions
within the data provided to us.
The five most commonly reported adverse events with the two
drugs were drowsiness or fatigue, ‘pins and needles’ (tingling sen-
sation), headache, gastrointestinal disturbance and anxiety or de-
pression. Rash and dizziness (feeling faint) were also commonly re-
ported with carbamazepine, and anorexia or weight loss was com-
monly reported with topiramate.
In Privitera 2003, 58 serious adverse events were reported in 29
individuals.
With topiramate 100 mg, there were 12 serious adverse events in
10 participants. One event of renal calculus in one participant,
and one event of grand mal convulsions in one participant, were
possibly related to treatment. All other events were unlikely to be
related to treatment: two events of grand mal convulsions in two
participants; and one event of ’regression’, one event of hypoten-
sion, one event of thrombophlebitis, one event of worsened con-
vulsions, one event of abnormal hepatic function, one event of
oedema, one event of asthenia and one event of aggravated depres-
sion (resulting in withdrawal of the drug), all in one participant
each.
With topiramate 200 mg, there were 29 serious adverse events in
11 participants. One event of renal calculus was very likely to be
related to the treatment and another event of renal calculus was
probably related to treatment. Nine events of confusion and ag-
gravated depression in one participant were also probably related
to treatment. The drug was withdrawn from these three partici-
pants. All other events were unlikely to be related to treatment:
two events of adenocarcinoma in one participant; three events of
dizziness, nausea and palpitations in one participant; eight events
of headache, back pain, confusion, fever and upper respiratory
tract infection in one participant; and one injury, one event of
asthma, one event of migraine, one event of ileus, one event of
chest pain and one event of foetal death, all in one participant
each. None of the unrelated adverse events resulted in withdrawal
of the drug.
On carbamazepine, there were 17 serious adverse events in eight
participants. One event of grand mal convulsions was very likely
to be related to the treatment. All other events were unlikely to be
related to treatment: seven events of diverticulitis andhypertension
in one participant; two events of enteritis in one participant; three
events of dyspnoea and chest pain in one participant; and one event
of syncope, one abscess, one injury and one case of abdominal
pain, all in one participant each. None of these events resulted in
withdrawal of treatments.
In SANAD A 2007, 179 events resulting in hospitalisation were
reported in 101 participants (not stated whether events were re-
lated to treatment).
On topiramate, there were 88 hospitalisation events in 55 partic-
ipants: 21 events of worsening seizures or status epilepticus in 13
participants (resulting in withdrawal of the drug in 2 participants);
accidental injuries in four participants; six events of headache in
three participants (resulting in withdrawal of the drug in 1 partic-
ipant); accidental drug overdoses in three participants; brain tu-
mours in three participants (resulting in withdrawal of the drug
in 1 participant); abdominal pain in three participants (resulting
in withdrawal of the drug in 1 participant); three coronary artery
bypass grafts in two participants; chest pain in two participants;
renal malignancy in two participants; depression in two partici-
pants; visual disturbances in two participants (resulting in with-
drawal of the drug in 1 participant); self-harm/suicide attempt in
two participants (resulting in withdrawal of the drug in one par-
ticipant); urinary tract infections in two participants; thrombosis
in two participants; three events of ataxia in one participant; three
events of Crohn’s disease in one participant; two events of dizziness
in one participant; and one cataract operation, one event of hyper-
tension, one event of sarcoidosis, one testicular lump, one event
of urinary incontinence, one miscarriage, one event of Henoch-
Schonlein purpura, one event of Steven Johnsons syndrome (re-
sulting in withdrawal of the drug), and one collapsed lung, all in
one participant each.
On carbamazepine, there were 91 hospitalisation events in 46 par-
ticipants: worsening of seizures in 12 participants; cardiovascular
events in five participants; attempted suicide in three participants;
seizure-related injury in three participants; allergic rash in two
participants; pneumonia in two participants; and antiphospho-
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lipid syndrome, arthritis, stomach cancer, urinary tract infection,
disorientation, psychotic illness (resulting in withdrawal of the
drug), exacerbation of chronic obstructive pulmonary disease, hys-
terectomy (resulting in withdrawal of the drug), torsion of testis,
myringotomy, infection, worsening of seizures and visual distur-
bance (resulting in withdrawal of the drug), constipation (result-
ing in withdrawal of the drug), low serum, breast cancer, abdom-
inal pain, ataxia, childbirth, and headache, all in one participant
each.
Summary of aggregate results reported in Resendiz-
Aparicio 2004
IPD were not available for the 88 participants randomised in
Resendiz-Aparicio 2004.
Forty-six participants were randomised to topiramate and 42 were
randomised to carbamazepine; 23 participants dropped out due to
adverse events, lack of efficacy or loss to follow-up (13 randomised
to topiramate and 10 randomised to carbamazepine). Results were
presented only for the 33 participants randomised to topiramate
and 32 randomised to carbamazepine who did not drop out of the
study.
Thirty participants on topiramate and 26 on carbamazepine
achieved six months of freedom from seizures after 12 months of
treatment and 32 participants receiving topiramate and 27 receiv-
ing carbamazepine achieved a 50% or more reduction in seizures
during the same time frame. The average number of seizures was
significantly lower in the topiramate group than in the carba-
mazepine group at six and nine months (P value of t-test = 0.01).
No clinically significant changes were observed in clinical or phys-
ical examinations in either group. Adverse event experiences were
mild and similar between groups: somnolence (in 3 receiving topi-
ramate and 6 receiving carbamazepine); dizziness (1 receiving top-
iramate and 2 receiving carbamazepine); weight loss or anorexia (5
receiving topiramate); gastritis (1 receiving topiramate); nausea (1
receiving topiramate); rash (1 receiving carbamazepine); headache
(1 receiving carbamazepine); uncontrolled seizures (1 receiving
carbamazepine).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Topiramate compared with carbamazepine for epilepsy (secondary outcomes)
Population: adults and children with newly onset focal or generalised epilepsy
Settings: outpat ients
Intervention: topiramate
Comparison: carbamazepine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Carbamazepine Topiramate
Time to first seizure af-
ter randomisation
All participants
Range of follow-up: 0 to
2420 days
The median t ime to f irst
seizure af ter randomi-
sat ion was 154 days
in the carbamazepine
group
The median t ime to f irst
seizure af ter randomi-
sat ion was 124 days
(30 days shorter) in the
topiramate group
HR 1.11
(0.96 to 1.29)a
1115
(2 studies)
⊕⊕⊕⊕
High
HR < 1 indicates a clin-
ical advantage for topi-
ramate
Time to first seizure af-
ter randomisation
Subgroup: focal onset
seizures
Range of follow-up: 0 to
2420 days
The median t ime to f irst
seizure af ter randomi-
sat ion was 95 days
in the carbamazepine
group
The median t ime to f irst
seizure af ter randomi-
sat ion was 90 days (5
days shorter) in the top-
iramate group
HR 1.12
(0.95 to 1.31)
925
(2 studies)
⊕⊕⊕⊕
High
HR < 1 indicates a clin-
ical advantage for topi-
ramate
Time to first seizure af-
ter randomisation
Subgroup: generalised on-
set tonic-clonic seizures or
unclassified epilepsy
Range of follow-up: 0 to
853 days
The median t ime to f irst
seizure af ter randomi-
sat ion was 495 days
in the carbamazepine
group
The median t ime to f irst
seizure af ter randomi-
sat ion was 393 days
(102 days shorter) in
the topiramate group
HR 1.08
(0.70 to 1.66)
190
(2 studies)
⊕⊕⊕©
Moderateb
HR < 1 indicates a clin-
ical advantage for topi-
ramate
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Time to 12-month re-
mission of seizures
All participants
Range of follow-up: 0 to
2420 days
The median t ime to
achieve 12-month re-
m ission was 484 days
in the carbamazepine
group
The median t ime to
achieve 12-month re-
m ission was 537 days
(53 days longer) in the
topiramate group
HR 0.84
(0.71 to 0.99)a
1115
(2 studies)
⊕⊕⊕⊕
High
HR < 1 indicates a clin-
ical advantage for car-
bamazepine
Time to 12-month re-
mission of seizures
Subgroup: focal onset
seizures
Range of follow-up: 0 to
2420 days
The median t ime to
achieve 12-month re-
m ission was 533 days
in the carbamazepine
group
The median t ime to
achieve 12-month re-
m ission was 582 days
(49 days longer) in the
topiramate group
HR 0.82
(0.69 to 0.99)
925
(2 studies)
⊕⊕⊕⊕
High
HR < 1 indicates a clin-
ical advantage for car-
bamazepine
Time to 12-month re-
mission of seizures
Subgroup: generalised on-
set tonic-clonic seizures or
unclassified epilepsy
Range of follow-up: 0 to
853 days
The median t ime to
achieve 12-month re-
m ission was 365 days
in the carbamazepine
group
The median t ime to
achieve 12-month re-
m ission was 365 days
(0 days longer) in the
topiramate group
HR 0.92
(0.61 to 1.41)
190
(2 studies)
⊕⊕⊕©
Moderateb
HR < 1 indicates a clin-
ical advantage for car-
bamazepine
* Illustrat ive risks in the topiramate and carbamazepine groups are calculated at the median t ime to f irst seizure or t ime to 12-month remission (i.e. the t ime to 50% of
part icipants experiencing a f irst seizure or 12-months of remission) within each group across all t rials. The relat ive ef fect (pooled hazard rat io) shows the comparison of ’t ime
to f irst seizure’ or ’t ime to 12-month remission’ between the treatment groups
CI: conf idence interval; HR: hazard rat io
GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect
Moderate certainty: : f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low certainty: we are very uncertain about the est imate
aPooled HR for all part icipants adjusted for seizure type.
bDowngraded once for imprecision and applicability, lim ited information on generalised seizure types and most part icipants
do not have a classif ied seizure type in this subgroup so the interpretat ion of this seizure type is unclear.
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D I S C U S S I O N
Summary of main results
Individual participant data (IPD) were available for two tri-
als recruiting 1151 participants to carbamazepine or topiramate
(Privitera 2003; SANAD A 2007). For the third trial, which re-
cruited 88 participants, we could not contact the original authors,
and sowe could not include IPD from this trial (Resendiz-Aparicio
2004). Overall, IPD were available for 93% of the total eligible
1239 participants.
This review provides moderate-certainty evidence showing no
statistically significant difference between topiramate and carba-
mazepine for our primary global efficacy outcome ’time to treat-
ment failure for any reason related to treatment’ (pooled hazard
ratio (HR) 1.16, 95% confidence interval (CI) 0.97 to 1.38) and
for ’time to treatment failure due to adverse events’ (pooled HR
1.02, 95% CI 0.82 to 1.27) and a statistically significant advan-
tage for carbamazepine over topiramate for ’time to treatment fail-
ure lack of efficacy’ (pooled HR 1.46, 95% CI 1.08 to 1.98) for
all participants including those with focal onset seizures, gener-
alised tonic-clonic seizures (with or without other seizure types)
and unclassified seizure types. A statistically significant advantage
(high-certainty evidence) for carbamazepine over topiramate was
also observed for secondary outcome ’time to 12-month remission’
(pooled HR 0.84, 95% CI 0.71 to 0.99) for all participants.
Considering only individuals with focal onset seizures (81% of
participants contributing to the analysis) results of this review pro-
vide high to moderate-certainty evidence. A statistically signifi-
cant advantage for carbamazepine over topiramate was observed
for our primary outcome ’time to treatment failure for any reason
related to treatment’ (pooled HR 1.21, 95% CI 1.01 to 1.46) and
for ’time to treatment failure lack of efficacy’ (pooled HR 1.47,
95% CI 1.07 to 2.02) but no differences were found between the
drugs in terms of ’time to treatment failure due to adverse events’
(pooled HR 1.08, 95% CI 0.85 to 1.36). As also observed for all
participants, for individuals with focal onset seizures, a statistically
significant advantage (high-certainty evidence) for carbamazepine
over topiramate was also observed for secondary outcome ’time to
12-month remission’ (pooled HR 0.82, 95% CI 0.69 to 0.99).
The results of this review (high- to moderate-certainty evidence)
also show no statistically significant difference between topiramate
and carbamazepine for our secondary outcomes of ’time to first
seizure’ and ’time to six-month remission’ for all individuals and
by seizure type.
Evidence for individuals with generalised tonic-clonic seizures
(with or without other seizure types) (9% of participants con-
tributing to the analysis), and unclassified seizure types (10% of
participants contributing to the analysis) was very limited and of
moderate to low certainty for all outcomes; no statistically signif-
icant differences were found but CIs were wide, therefore we can-
not exclude an advantage to either drug, or no difference between
drugs for generalised onset seizures and unclassified epilepsy.
The five most commonly reported adverse events with the two
drugs were drowsiness or fatigue, ‘pins and needles’ (tingling sen-
sation), headache, gastrointestinal disturbance and anxiety or de-
pression. Rash and dizziness (feeling faint) were also commonly re-
ported with carbamazepine, and anorexia or weight loss was com-
monly reported with topiramate. The rates of adverse events and
serious adverse events were similar across the two drugs.
Overall completeness and applicability of
evidence
We believe our systematic electronic searches identified all relevant
evidence for this review. We gratefully received IPD for 1151 indi-
viduals (93% of 1239 individuals from all eligible trials) from the
authors or sponsors of two trials (Privitera 2003; SANADA2007),
that included a comparison of topiramate with carbamazepine for
the treatment of epilepsy.
At the time the review was conducted, we were unable to obtain
IPD for the remaining trial (Resendiz-Aparicio 2004), which ran-
domised a total of 88 participants. We were not able to make con-
tact with a study author. If we receive IPD from this trial, we will
include them in future review updates. We do not believe that our
failure to obtain IPD from 7% of eligible participants from this
single trial has had a large impact on the applicability of the results
of the review.
Eligible seizure types included in this review were focal onset and
generalised tonic-clonic (with or without other generalised types).
Due to the design of the two studies contributing to analysis, a
majority of participants recruited into these trials experienced focal
onset seizures (82% of participants contributing to the analysis)
and the majority of the remaining participants had an unclassified
seizure type.
As a result, the results of this review are primarily applicable to
participants with focal onset seizures and we encourage caution in
the interpretation of results for the small subgroup of participants
who had generalised onset or unclassified epilepsy.
Quality of the evidence
The two trials for which IPD were made available (as well as
additional trial design information from trial authors/sponsors)
were generally of good quality. One of the trials was double-blind
(Privitera 2003), and onewas open-label (SANADA2007).While
it is argued that an open-label design is more pragmatic and re-
flective of the ’real world’ treatment of a chronic condition, such
as epilepsy, where treatments are likely to be taken long term by
participants ( SANAD A 2007), significantly more participants
withdrew from treatment in the open-label study than in the dou-
ble-blind study (51% versus 44%, Chi2 P = 0.03). Both of the
trials contributing to analysis in this review compared a ’new’ in-
tervention with a ’standard’ intervention, and knowledge of the
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treatment allocation may have influenced the choice of the partic-
ipant or clinician to continue taking the treatment. This, in turn,
may have influenced the perceived effectiveness of the two drugs
under comparison. We have, therefore, considered an open-label
design to potentially introduce bias into the results for the subjec-
tive outcome of time to treatment failure, but not for the objective
secondary outcomes of time to first seizure and remission.
Due to the potential risk of bias from an open-label design, we have
rated the evidence provided in this review, according to GRADE
criteria, for our primary outcome of time to treatment failure as
‘moderate certainty’ for all participants and the subgroup of partic-
ipants with focal onset seizures. Due to the limited number of par-
ticipants with generalised onset seizures (and, hence, the potential
misclassification of seizure type), we have rated this evidence as
low certainty for the primary outcome, see Summary of findings
for the main comparison. For our secondary (objective) outcomes
of time to first seizure and remission, we have rated evidence as
high certainty (moderate certainty in the subgroup of participants
with generalised onset seizures for the reasons stated above) (see
Summary of findings 2).
Potential biases in the review process
We were able to include IPD for 1151 of 1239 eligible partici-
pants (93%) from two of three trials in this review and were able
to analyse all outcomes using IPD. Such an approach has many
advantages, such as allowing the standardisation of definitions of
outcomes across trials. In addition, attrition and reporting biases
are reduced as we can perform additional analyses and calculate
additional outcomes from unpublished data. For the outcomes we
used in this review that are of a time-to-event nature, an IPD ap-
proach is considered to be the ’gold standard’ approach to analysis
(Parmar 1998).
For reasons outside of our control, we were unable to obtain IPD
for 88 participants from one trial for inclusion in this review.
However, we do not believe that the exclusion of 7% of eligible
participants is likely to have impacted on the conclusions of this
review (see Overall completeness and applicability of evidence).
Finally, we made some assumptions in the statistical methodology
used in this review. First, when we received only follow-up dates
and seizure frequencies from the authors of the included studies,
we used linear interpolation to estimate approximate seizure dates.
We are aware that an individual’s seizure patterns may be non-
linear; therefore, we recommend caution when interpreting the
numerical results of the seizure-related outcomes.
We also made an assumption that treatment effect for each out-
come did not change over time (proportional hazards assumption,
see Data synthesis). We are aware that in trials of long duration
(e.g. SANAD A 2007, which was of over one year in duration),
the assumption that treatment effect remains constant over time
is unlikely to be appropriate; for example, there is likely to be a
difference between participants who achieve immediate remission
compared with participants who achieve later remission. There-
fore, if future updates of this review include more trials of long
duration, we would like to perform statistical analyses that allow
for treatment effects to vary over time.
Agreements and disagreements with other
studies or reviews
Toour knowledge, this is the only systematic review andmeta-anal-
ysis that compares topiramate and carbamazepine monotherapy
for focal onset seizures and generalised onset tonic-clonic seizures.
A networkmeta-analysis has been published (Nevitt 2017a), com-
paring all direct and indirect evidence from topiramate, carba-
mazepine, and other standard and new antiepileptic drugs (AEDs)
licensed for monotherapy. The results of this review generally
agree with the results of the network meta-analysis; results of this
network meta-analysis showed a potential advantage for carba-
mazepine compared with topiramate which was not statistically
significant for all outcomes (time to treatment failure, time to first
seizure and time to six-month and 12-month remission). No sta-
tistically significant differences were found between the drugs for
all outcomes for participants with generalised onset seizures.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Current UK guidelines recommend carbamazepine or lamotrig-
ine as first-line treatment for adults and children with new-on-
set focal seizures, and sodium valproate for adults and children
with new-onset generalised seizures. Topiramate is not currently
recommended as a first- or second-line treatment for use in new-
onset focal or generalised seizures (NICE 2012). The results of
this review do not provide any conclusive evidence for or against
these guidelines.
There is some suggestion from the moderate-certainty evidence
provided by the results of this review that carbamazepine may be a
more effective drug for individuals with new-onset focal seizures in
terms of treatment retention (treatment failure due to lack of effi-
cacy, or adverse events, or both occurred later with carbamazepine)
and that these individuals may achieve a year of remission from
seizures earlier with carbamazepine than with topiramate. How-
ever, this differencewas not observed for recurrence of a first seizure
and for remission of a shorter period.
For individuals with new-onset generalised tonic-clonic seizures
(with or without other generalised seizure types), the evidence in
the review is limited due to the small numbers of participants with
generalised seizure types recruited into the included trials. Fur-
thermore, an important proportion of individuals had unclassified
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seizure types, and evidence is limited and inconclusive for these
participants.
There is evidence that carbamazepine may exacerbate some gen-
eralised seizure types, and so should be used with caution in indi-
viduals with this seizure type (Liporace 1994; Shields 1983; Snead
1985). Topiramate may be an effective alternative treatment op-
tion to sodium valproate for new-onset generalised seizures, but
more evidence is required to confirm this (NICE 2012). Newer
antiepileptic drugs (AEDs), such as topiramate, may be associated
with less intolerable side effects than older drugs, such as carba-
mazepine (French 2007); however, the results of the review do not
suggest that topiramate is better- or worse-tolerated than carba-
mazepine.
Implications for research
Results of this review are taken from the synthesis of 1151 of 1239
eligible participants from two of three eligible trials. Some of the
pooled results from the two studies included in this review sug-
gested a potential advantage for carbamazepine over topiramate
but these results did not reach statistical significance; we therefore
do not rule out that important differences may exist between the
drugs which may come to light if more evidence can be incorpo-
rated into the review during future updates.
This review highlights the need for the design of future AED
monotherapy trials that recruit individuals with specific epilepsy
syndromes to be powered to detect a difference between particular
AEDs. An approach likely to reflect and inform clinical practice,
as well as being statistically powerful, would be to recruit hetero-
geneous populations for whom epilepsy syndromes have been ad-
equately defined, with testing for interactions between treatments
and epilepsy syndromes.
In view of potential problems arising fromunclassified seizures and
the misclassification of seizure type, it is important that epilepsy
syndromes should be well defined in the inclusion criteria of fu-
ture trials, with adequate checking mechanisms to ensure that
classifications are accurate and a system to recognise uncertainty
surrounding epilepsy syndromes in individuals within trials. This
most commonly applies to tonic-clonic seizures that may be gen-
eralised at onset, or which may be secondarily generalised. In any
trial, such unclassified individuals need to be clearly identified,
because if they are not they may confound the interpretation of
the results for well-classified individuals. We need to know how to
manage participants whose classification we find more difficult.
It is also important that future trials are of a sufficient duration
to measure the long-term effectiveness of AEDs - treatments that
will be life-long for many individuals with epilepsy - as well as
psychosocial, quality of life and health economic outcomes. Con-
sideration is also required in the design of a trial regarding whether
to blind participants and outcome assessors to treatment alloca-
tion. While an open-label design is a more pragmatic and practi-
cal approach for large long-term trials, when trials compare a new
intervention with an established ’standard’ intervention, masking
of treatment may be important to avoid preconceptions over the
relative effectiveness of the drugs.
The choice of outcomes at the design stage of a trial and the pre-
sentation of the results of outcomes, particularly of a time-to-
event nature, require very careful consideration. While the major-
ity of trials of a monotherapy design record an outcomemeasuring
efficacy (seizure control) and an outcome measuring tolerability
(adverse events), there is little uniformity between the definition
of the outcomes and the reporting of the summary statistics re-
lated to the outcomes (Nolan 2013a), making an aggregate data
approach to meta-analysis in reviews of monotherapy trials im-
possible. Where trial authors cannot or will not make individual
participant data (IPD) available for analysis, we are left with no
choice but to exclude a proportion of relevant evidence from the
review, which may impact upon the interpretation of the results of
the review and the applicability of the evidence and conclusions.
The International League Against Epilepsy recommends that tri-
als of a monotherapy design should adopt a primary effectiveness
outcome of ’time to treatment failure (retention time)’ and should
be of a duration of at least 48 weeks to allow for the assessment
of longer-term outcomes, such as remission (ILAE 1998; ILAE
2006). If trials followed these recommendations, an aggregate data
approach tometa-analysis could be feasible, reducing the resources
and time required by an IPD approach.
A network meta-analysis has also been published ( Nevitt 2017a),
comparing all direct and indirect evidence from topiramate, car-
bamazepine, and other standard and new AEDs licensed for
monotherapy. This networkmeta-analysis will be updated as more
information becomes available; however, we acknowledge that as
topiramate is not considered to be a first-line agent for individuals
with a new diagnosis of the seizure types within this review, it is
unlikely that a substantial amount of new evidence will become
available for this review.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Privitera 2003
Methods Multinational, randomised, double-blind trial conducted at 115 centres across the USA,
Canada, Europe and South America
Four treatments: CBZ, SV and TPM (2 arms, 100 mg/day and 200 mg/day) (see Notes)
Participants Participants over the age of 6 years and over 30 kg in weight, with a diagnosis of epilepsy
within the three months before trial entry and no previous AED treatment except emer-
gency treatment
Number randomised (ITT population): CBZ = 129, TPM = 266 (CBZ branch)
215 male participants (54%)
322 participants with focal epilepsy (82%)
Mean age (range): 34 (6 to 80 years)
Interventions Monotherapy with CBZ or TPM
Starting doses: CBZ = 200 mg/day, TPM = 25 mg/day
Target doses (after 4 week titration): CBZ = 600 mg/day, TPM = 100 or 200 mg/day
(see Notes)
Range of follow-up: 0 to 29 months
Outcomes Time to exit from the study
Time to first seizure
Proportionof seizure-free participants during the last 6months of double-blind treatment
Safety assessment: most commonly occurring adverse events
Notes IPD provided for all outcomes of this review by trial sponsor Johnson & Johnson. Trial
designed in two strata based on whether recommended treatment would be CBZ or SV.
Within the two strata, participants were randomised to 100 mg/day TPM, 200 mg/day
TPM or CBZ/SV depending on the strata. Data analysed according to the separate strata
in this review with the two TPM doses analysed together; separate doses of TPM are
considered in sensitivity analysis (see Data extraction and management)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was balanced using per-
muted blocks of size three and stratified by
trial centre, according to a computer-gen-
erated randomisation schedule prepared by
the trial sponsor
Allocation concealment (selection bias) Unclear risk No information provided
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Privitera 2003 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial was double-blinded for the first 6
months, followed by an open-label phase
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported, ITT approach,
all randomised participants from the ITT
population analysed from IPD provided
(see footnote 2). Eight participants with
no follow-up data were excluded from ITT
population
Selective reporting (reporting bias) Low risk All outcomes reported or calculated with
IPD provided (see footnote 2)
Other bias Low risk None identified
Resendiz-Aparicio 2004
Methods Randomised open-label trial conducted in several hospitals in Mexico
Two treatment arms: CBZ and TPM
Participants Participants between 2 and 18 years with newly diagnosed focal epilepsy (with or without
secondary generalisation) with at least two unprovoked seizures more than 24 hours
apart and at least one seizure in the last 6 months. Participants must have no established
treatment and have received no antiepileptic treatment within the past 30 days
Number randomised: CBZ = 42, TPM = 46. Number included in analysis CBZ = 32,
TPM = 33
100% focal epilepsy
33 male participants (60%) included in analysis
Mean age (range): CBZ = 10 (5 to 17) years, TPM = 8 (2 to 16) years for participants
included in analysis
Interventions Monotherapy with CBZ or TPM
Treatments titrated to a maximum of CBZ = 20 to 25 mg/kg/day, TPM = 9 mg/kg/day
Follow-up assessments at 6 and 9 months, range of follow-up not stated
Outcomes Seizure freedom and frequency of seizures during the trial
Adverse events during the trial
Laboratory results
Notes The trial was published in Spanish; the characteristics and outcomes were translated.
Outcomes chosen for this review were not reported; contact could not be made with
trial author to provide IPD
Results presented only for those who completed the trial. Those with less than 35%
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Resendiz-Aparicio 2004 (Continued)
reduction of seizures were excluded from analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number tables used to assign par-
ticipants to treatment groups
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label trial
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition rates reported (23 drops outs, 10
forCBZ and 13 for TPM).Only those who
completed the trial were included in analy-
sis (non responders to treatment excluded)
, this is not an ITT approach
Selective reporting (reporting bias) Low risk No protocol available. Seizure outcomes
and adverse events well reported
Other bias Low risk None identified
SANAD A 2007
Methods Randomised, multicentre, open-label, parallel-group trial conducted in the UK
Five treatment arms: LTG, CBZ, GBP, TPM and OXC
Participants Adults and children over the age of 4 years with newly diagnosed focal epilepsy, relapsed
focal epilepsy or failed treatment with a previous drug not used in this trial
Number randomised: CBZ = 378, TPM = 378
408 male participants (54%)
654 focal epilepsy (97%)
139 had received previous AED treatment (18%)
Mean age (range): 39 (5 to 86) years
Interventions Monotherapy for CBZ or TPM
Titration doses and maintenance doses decided by treating clinician
Range of follow-up: 0 to 86 months
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SANAD A 2007 (Continued)
Outcomes Time to treatment failure
Time to 1 year (12 month) remission
Time to 2 year remission
Time to first seizure
Health-related quality of life via the NEWQOL (Newly Diagnosed Epilepsy Quality of
Life Battery)
Health economic assessment and cost-effectiveness of the drugs (cost per QALY gained
and cost per seizure avoided)
Frequency of clinically important adverse events
Notes IPD provided for time to treatment failure, time to first seizure, time to 6-month remis-
sion, time to 12-month remission (trial co-ordinated at our site)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer minimisation programme strat-
ified by centre, sex and treatment history
Allocation concealment (selection bias) Low risk Telephone randomisation to a central ran-
domisation allocation service
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported, all randomised
participants analysed from IPD provided
(see footnote 2)
Selective reporting (reporting bias) Low risk Protocol provided. All outcomes reported
or calculated with IPD provided (see foot-
note 2)
Other bias Low risk None identified
Abbreviations
AED: antiepileptic drug; CBZ: carbamazepine; GBP: gabapentin; IPD: individual participant data, ITT: intention-to-treat; LTG:
lamotrigine; OXC: oxcarbazepine; QALY: quality-adjusted life-year; SV: sodium valproate; TPM: topiramate
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Kang 2007 Ineligible epilepsy type
48Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Topiramate monotherapy versus carbamazepine monotherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to treatment failure (any
reason related to the treatment)
2 1129 Hazard Ratio (Fixed, 95% CI) 1.15 [0.97, 1.37]
2 Time to treatment failure due to
adverse events
2 1129 Hazard Ratio (Fixed, 95% CI) 1.01 [0.82, 1.26]
3 Time to treatment failure due to
lack of efficacy
2 1129 Hazard Ratio (Fixed, 95% CI) 1.45 [1.08, 1.96]
4 Time to treatment failure (any
reason related to the treatment)
- by epilepsy type
2 1129 Hazard Ratio (Fixed, 95% CI) 1.16 [0.97, 1.38]
4.1 Focal onset 2 937 Hazard Ratio (Fixed, 95% CI) 1.21 [1.01, 1.46]
4.2 Generalised onset or
unclassified epilepsy
2 192 Hazard Ratio (Fixed, 95% CI) 0.88 [0.56, 1.39]
5 Time to treatment failure due
to adverse events - by epilepsy
type
2 1129 Hazard Ratio (Fixed, 95% CI) 1.02 [0.82, 1.27]
5.1 Focal onset 2 937 Hazard Ratio (Fixed, 95% CI) 1.08 [0.85, 1.36]
5.2 Generalised onset or
unclassified epilepsy
2 192 Hazard Ratio (Fixed, 95% CI) 0.72 [0.39, 1.31]
6 Time to treatment failure due to
lack of efficacy - by epilepsy
type
2 1129 Hazard Ratio (Fixed, 95% CI) 1.46 [1.08, 1.98]
6.1 Focal onset 2 937 Hazard Ratio (Fixed, 95% CI) 1.47 [1.07, 2.02]
6.2 Generalised onset or
unclassified epilepsy
2 192 Hazard Ratio (Fixed, 95% CI) 1.41 [0.54, 3.67]
7 Time to first seizure after
randomisation
2 1115 Hazard Ratio (Fixed, 95% CI) 1.09 [0.94, 1.27]
8 Time to first seizure after
randomisation - by epilepsy
type
2 1115 Hazard Ratio (Fixed, 95% CI) 1.11 [0.96, 1.29]
8.1 Focal onset 2 925 Hazard Ratio (Fixed, 95% CI) 1.12 [0.95, 1.31]
8.2 Generalised onset or
unclassified epilepsy
2 190 Hazard Ratio (Fixed, 95% CI) 1.08 [0.70, 1.66]
9 Time to 12-month remission of
seizures
2 1115 Hazard Ratio (Fixed, 95% CI) 0.85 [0.72, 1.01]
10 Time to 12-month remission
of seizures - by epilepsy type
2 1115 Hazard Ratio (Fixed, 95% CI) 0.84 [0.71, 0.99]
10.1 Focal onset 2 925 Hazard Ratio (Fixed, 95% CI) 0.82 [0.69, 0.99]
10.2 Generalised onset or
unclassified epilepsy
2 190 Hazard Ratio (Fixed, 95% CI) 0.92 [0.61, 1.41]
11 Time to 6-month remission of
seizures
2 1115 Hazard Ratio (Fixed, 95% CI) 0.88 [0.76, 1.01]
49Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
12 Time to 6-month remission of
seizures - by epilepsy type
2 1115 Hazard Ratio (Fixed, 95% CI) 0.87 [0.76, 1.01]
12.1 Focal onset 2 925 Hazard Ratio (Fixed, 95% CI) 0.86 [0.74, 1.01]
12.2 Generalised onset or
unclassified epilepsy
2 190 Hazard Ratio (Fixed, 95% CI) 0.93 [0.66, 1.30]
Analysis 1.1. Comparison 1 Topiramate monotherapy versus carbamazepine monotherapy, Outcome 1
Time to treatment failure (any reason related to the treatment).
Review: Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Topiramate monotherapy versus carbamazepine monotherapy
Outcome: 1 Time to treatment failure (any reason related to the treatment)
Study or subgroup Topiramate (TPM)
Carbamazepine
(CBZ) log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Privitera 2003 266 129 0.0303825 (0.1640957) 28.6 % 1.03 [ 0.75, 1.42 ]
SANAD A 2007 366 368 0.1863111 (0.1039771) 71.4 % 1.20 [ 0.98, 1.48 ]
Total (95% CI) 632 497 100.0 % 1.15 [ 0.97, 1.37 ]
Heterogeneity: Chi2 = 0.64, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours topiramate Favours carbamazepine
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Analysis 1.2. Comparison 1 Topiramate monotherapy versus carbamazepine monotherapy, Outcome 2
Time to treatment failure due to adverse events.
Review: Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Topiramate monotherapy versus carbamazepine monotherapy
Outcome: 2 Time to treatment failure due to adverse events
Study or subgroup Topiramate (TPM)
Carbamazepine
(CBZ) log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Privitera 2003 266 129 -0.1962809 (0.2216186) 24.5 % 0.82 [ 0.53, 1.27 ]
SANAD A 2007 366 368 0.0811546 (0.1263258) 75.5 % 1.08 [ 0.85, 1.39 ]
Total (95% CI) 632 497 100.0 % 1.01 [ 0.82, 1.26 ]
Heterogeneity: Chi2 = 1.18, df = 1 (P = 0.28); I2 =15%
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours topiramate Favours carbamazepine
Analysis 1.3. Comparison 1 Topiramate monotherapy versus carbamazepine monotherapy, Outcome 3
Time to treatment failure due to lack of efficacy.
Review: Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Topiramate monotherapy versus carbamazepine monotherapy
Outcome: 3 Time to treatment failure due to lack of efficacy
Study or subgroup Topiramate (TPM)
Carbamazepine
(CBZ) log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Privitera 2003 266 129 0.3656053 (0.3637095) 17.9 % 1.44 [ 0.71, 2.94 ]
SANAD A 2007 366 368 0.3758762 (0.1696359) 82.1 % 1.46 [ 1.04, 2.03 ]
Total (95% CI) 632 497 100.0 % 1.45 [ 1.08, 1.96 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 2.43 (P = 0.015)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Topiramate monotherapy versus carbamazepine monotherapy, Outcome 4
Time to treatment failure (any reason related to the treatment) - by epilepsy type.
Review: Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Topiramate monotherapy versus carbamazepine monotherapy
Outcome: 4 Time to treatment failure (any reason related to the treatment) - by epilepsy type
Study or subgroup Topiramate (TPM)
Carbamazepine
(CBZ) log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset
Privitera 2003 194 91 0.1454118 (0.1944018) 20.5 % 1.16 [ 0.79, 1.69 ]
SANAD A 2007 319 333 0.2065003 (0.1091812) 65.1 % 1.23 [ 0.99, 1.52 ]
Subtotal (95% CI) 513 424 85.6 % 1.21 [ 1.01, 1.46 ]
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 2.02 (P = 0.044)
2 Generalised onset or unclassified epilepsy
Privitera 2003 72 38 -0.2873704 (0.3121317) 8.0 % 0.75 [ 0.41, 1.38 ]
SANAD A 2007 47 35 0.0749658 (0.3462861) 6.5 % 1.08 [ 0.55, 2.12 ]
Subtotal (95% CI) 119 73 14.4 % 0.88 [ 0.56, 1.39 ]
Heterogeneity: Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
Total (95% CI) 632 497 100.0 % 1.16 [ 0.97, 1.38 ]
Heterogeneity: Chi2 = 2.28, df = 3 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.66 (P = 0.097)
Test for subgroup differences: Chi2 = 1.60, df = 1 (P = 0.21), I2 =37%
0.01 0.1 1 10 100
Favours topiramate Favours carbamazepine
52Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.5. Comparison 1 Topiramate monotherapy versus carbamazepine monotherapy, Outcome 5
Time to treatment failure due to adverse events - by epilepsy type.
Review: Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Topiramate monotherapy versus carbamazepine monotherapy
Outcome: 5 Time to treatment failure due to adverse events - by epilepsy type
Study or subgroup Topiramate (TPM)
Carbamazepine
(CBZ) log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset
Privitera 2003 194 91 -0.1028121 (0.2563362) 18.4 % 0.90 [ 0.55, 1.49 ]
SANAD A 2007 319 333 0.1213176 (0.13256) 68.7 % 1.13 [ 0.87, 1.46 ]
Subtotal (95% CI) 513 424 87.1 % 1.08 [ 0.85, 1.36 ]
Heterogeneity: Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
2 Generalised onset or unclassified epilepsy
Privitera 2003 72 38 -0.4874456 (0.4497156) 6.0 % 0.61 [ 0.25, 1.48 ]
SANAD A 2007 47 35 -0.1944494 (0.417502) 6.9 % 0.82 [ 0.36, 1.87 ]
Subtotal (95% CI) 119 73 12.9 % 0.72 [ 0.39, 1.31 ]
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.08 (P = 0.28)
Total (95% CI) 632 497 100.0 % 1.02 [ 0.82, 1.27 ]
Heterogeneity: Chi2 = 2.35, df = 3 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Chi2 = 1.52, df = 1 (P = 0.22), I2 =34%
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Analysis 1.6. Comparison 1 Topiramate monotherapy versus carbamazepine monotherapy, Outcome 6
Time to treatment failure due to lack of efficacy - by epilepsy type.
Review: Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Topiramate monotherapy versus carbamazepine monotherapy
Outcome: 6 Time to treatment failure due to lack of efficacy - by epilepsy type
Study or subgroup Topiramate (TPM)
Carbamazepine
(CBZ) log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset
Privitera 2003 194 91 0.5014322 (0.4276748) 13.1 % 1.65 [ 0.71, 3.82 ]
SANAD A 2007 319 333 0.3636513 (0.1766023) 76.8 % 1.44 [ 1.02, 2.03 ]
Subtotal (95% CI) 513 424 89.9 % 1.47 [ 1.07, 2.02 ]
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 2.35 (P = 0.019)
2 Generalised onset or unclassified epilepsy
Privitera 2003 72 38 -0.0383977 (0.7079196) 4.8 % 0.96 [ 0.24, 3.85 ]
SANAD A 2007 47 35 0.6882941 (0.6707901) 5.3 % 1.99 [ 0.53, 7.41 ]
Subtotal (95% CI) 119 73 10.1 % 1.41 [ 0.54, 3.67 ]
Heterogeneity: Chi2 = 0.56, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
Total (95% CI) 632 497 100.0 % 1.46 [ 1.08, 1.98 ]
Heterogeneity: Chi2 = 0.65, df = 3 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 2.45 (P = 0.014)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.94), I2 =0.0%
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Analysis 1.7. Comparison 1 Topiramate monotherapy versus carbamazepine monotherapy, Outcome 7
Time to first seizure after randomisation.
Review: Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Topiramate monotherapy versus carbamazepine monotherapy
Outcome: 7 Time to first seizure after randomisation
Study or subgroup Topiramate (TPM)
Carbamazepine
(CBZ) log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Privitera 2003 266 129 0.2738381 (0.1623253) 22.2 % 1.32 [ 0.96, 1.81 ]
SANAD A 2007 358 362 0.0373292 (0.0866621) 77.8 % 1.04 [ 0.88, 1.23 ]
Total (95% CI) 624 491 100.0 % 1.09 [ 0.94, 1.27 ]
Heterogeneity: Chi2 = 1.65, df = 1 (P = 0.20); I2 =39%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Topiramate monotherapy versus carbamazepine monotherapy, Outcome 8
Time to first seizure after randomisation - by epilepsy type.
Review: Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Topiramate monotherapy versus carbamazepine monotherapy
Outcome: 8 Time to first seizure after randomisation - by epilepsy type
Study or subgroup Topiramate (TPM)
Carbamazepine
(CBZ) log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset
Privitera 2003 194 91 0.1932757 (0.1834128) 17.4 % 1.21 [ 0.85, 1.74 ]
SANAD A 2007 312 328 0.0879804 (0.0912451) 70.3 % 1.09 [ 0.91, 1.31 ]
Subtotal (95% CI) 506 419 87.7 % 1.12 [ 0.95, 1.31 ]
Heterogeneity: Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.33 (P = 0.18)
2 Generalised onset or unclassified epilepsy
Privitera 2003 72 38 0.5138895 (0.3499663) 4.8 % 1.67 [ 0.84, 3.32 ]
SANAD A 2007 46 34 -0.2027549 (0.2796458) 7.5 % 0.82 [ 0.47, 1.41 ]
Subtotal (95% CI) 118 72 12.3 % 1.08 [ 0.70, 1.66 ]
Heterogeneity: Chi2 = 2.56, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 0.35 (P = 0.73)
Total (95% CI) 624 491 100.0 % 1.11 [ 0.96, 1.29 ]
Heterogeneity: Chi2 = 2.84, df = 3 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
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Analysis 1.9. Comparison 1 Topiramate monotherapy versus carbamazepine monotherapy, Outcome 9
Time to 12-month remission of seizures.
Review: Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Topiramate monotherapy versus carbamazepine monotherapy
Outcome: 9 Time to 12-month remission of seizures
Study or subgroup Topiramate (TPM)
Carbamazepine
(CBZ) log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Privitera 2003 266 129 -0.1968302 (0.2441061) 12.3 % 0.82 [ 0.51, 1.33 ]
SANAD A 2007 358 362 -0.1527401 (0.0916063) 87.7 % 0.86 [ 0.72, 1.03 ]
Total (95% CI) 624 491 100.0 % 0.85 [ 0.72, 1.01 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.84 (P = 0.065)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Topiramate monotherapy versus carbamazepine monotherapy, Outcome 10
Time to 12-month remission of seizures - by epilepsy type.
Review: Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Topiramate monotherapy versus carbamazepine monotherapy
Outcome: 10 Time to 12-month remission of seizures - by epilepsy type
Study or subgroup Topiramate (TPM)
Carbamazepine
(CBZ) log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset
Privitera 2003 194 91 -0.0751375 (0.313314) 7.6 % 0.93 [ 0.50, 1.71 ]
SANAD A 2007 312 328 -0.2050888 (0.0985933) 76.3 % 0.81 [ 0.67, 0.99 ]
Subtotal (95% CI) 506 419 83.9 % 0.82 [ 0.69, 0.99 ]
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 2.06 (P = 0.040)
2 Generalised onset or unclassified epilepsy
Privitera 2003 72 38 -0.4542794 (0.3929632) 4.8 % 0.63 [ 0.29, 1.37 ]
SANAD A 2007 46 34 0.0786113 (0.2563729) 11.3 % 1.08 [ 0.65, 1.79 ]
Subtotal (95% CI) 118 72 16.1 % 0.92 [ 0.61, 1.41 ]
Heterogeneity: Chi2 = 1.29, df = 1 (P = 0.26); I2 =22%
Test for overall effect: Z = 0.37 (P = 0.71)
Total (95% CI) 624 491 100.0 % 0.84 [ 0.71, 0.99 ]
Heterogeneity: Chi2 = 1.68, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 2.03 (P = 0.042)
Test for subgroup differences: Chi2 = 0.23, df = 1 (P = 0.63), I2 =0.0%
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Analysis 1.11. Comparison 1 Topiramate monotherapy versus carbamazepine monotherapy, Outcome 11
Time to 6-month remission of seizures.
Review: Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Topiramate monotherapy versus carbamazepine monotherapy
Outcome: 11 Time to 6-month remission of seizures
Study or subgroup Topiramate (TPM)
Carbamazepine
(CBZ) log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Privitera 2003 266 129 -0.1311534 (0.1526635) 22.3 % 0.88 [ 0.65, 1.18 ]
SANAD A 2007 358 362 -0.1312921 (0.0818422) 77.7 % 0.88 [ 0.75, 1.03 ]
Total (95% CI) 624 491 100.0 % 0.88 [ 0.76, 1.01 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.82 (P = 0.069)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Topiramate monotherapy versus carbamazepine monotherapy, Outcome 12
Time to 6-month remission of seizures - by epilepsy type.
Review: Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Topiramate monotherapy versus carbamazepine monotherapy
Outcome: 12 Time to 6-month remission of seizures - by epilepsy type
Study or subgroup Topiramate (TPM)
Carbamazepine
(CBZ) log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset
Privitera 2003 194 91 -0.056424 (0.1887076) 14.7 % 0.95 [ 0.65, 1.37 ]
SANAD A 2007 312 328 -0.1699507 (0.0883258) 67.3 % 0.84 [ 0.71, 1.00 ]
Subtotal (95% CI) 506 419 82.0 % 0.86 [ 0.74, 1.01 ]
Heterogeneity: Chi2 = 0.30, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.87 (P = 0.062)
2 Generalised onset or unclassified epilepsy
Privitera 2003 72 38 -0.3022575 (0.2608868) 7.7 % 0.74 [ 0.44, 1.23 ]
SANAD A 2007 46 34 0.0977955 (0.2257319) 10.3 % 1.10 [ 0.71, 1.72 ]
Subtotal (95% CI) 118 72 18.0 % 0.93 [ 0.66, 1.30 ]
Heterogeneity: Chi2 = 1.34, df = 1 (P = 0.25); I2 =26%
Test for overall effect: Z = 0.43 (P = 0.67)
Total (95% CI) 624 491 100.0 % 0.87 [ 0.76, 1.01 ]
Heterogeneity: Chi2 = 1.80, df = 3 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.88 (P = 0.061)
Test for subgroup differences: Chi2 = 0.16, df = 1 (P = 0.69), I2 =0.0%
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A D D I T I O N A L T A B L E S
Table 1. Demographic characteristics of trial participants (trials providing IPD)
Characteristic Privitera 2003 SANAD A 2007
CBZ TPM Missing CBZ TPM Missing
Focal seizures n
(%)
91 (71) 194 (73) 22 333 (88) 321 (85) 89
Male gender
n (%)
68 (52) 147 (55) 0 204 (55) 204 (55) 18
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Table 1. Demographic characteristics of trial participants (trials providing IPD) (Continued)
Abnormal neu-
rological
exam, n (%)
NA NA 395 87 (24) 105 (28) 18
Age at entry
(years),
mean (SD),
range
35.4 (18.7), 6 to
80
33.9 (18.2), 6 to
75
0 39.3 (18.4), 5 to 82 38.7 (18.6), 5 to 86 18
Number of
seizures in prior
6 months: me-
dian (range)
4 (0 to 2400) 4 (0 to 1346) 0 4 (0 to 467) 4 (0 to 393) 21
CBZ = carbamazepine, TPM = topiramate, NA = not available, SD = standard deviation
Table 2. Number of participants included in analyses (trials providing IPD)
Privitera 2003 SANAD A 2007a Total
CBZ TPM Total CBZ TPM Total CBZ TPM Total
Number
ran-
domised
129 266 395 378 378 756 507 644 1151
Time to
treatment
failure
129 266 395 368 366 734 497 632 1129
Time to
first
seizure
129 266 395 362 358 720 491 624 1115
Time to 6
and
12-month
remission
129 266 395 362 358 720 491 624 1115
CBZ = carbamazepine, TPM = topiramate
aWithdrawal time missing for 22 participants and seizure data after follow-up missing for 36 participants in SANAD A 2007.
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Table 3. Reasons for premature discontinuation (treatment failure) in trials providing IPD
Study Privitera 2003 SANAD A 2007e Grand
Total
Reason
(and clas-
sification
in analy-
sis)
CBZ TPM
100 mg/
day
TPM
200 mg/
day
TPM
(pooled)
Total CBZ TPM Total
Com-
pleted
study
(Cen-
sored)
63 64 66 130 193 151 137 288 481
Ad-
verse event
(Event)
32 26 30 56 88 104 103 207 295
Ineffective
treatment
(Event)
10 18 13 31 41 43 55 98 139
Other rea-
son
(Event)b
7 9 8 17 24 10 16 26 50
Both inef-
fective
treatment
and
adverse
events
(Event)
0 0 0 0 0 20 28 48 48
Remis-
sion (Cen-
sored)
0 0 0 0 0 25 19 44 44
Other rea-
son (Cen-
sored)c
3 4 2 6 9 19 12 31 40
Participant
choice
(Event)d
5 9 7 16 21 6 8 14 35
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Table 3. Reasons for premature discontinuation (treatment failure) in trials providing IPD (Continued)
Lost to fol-
low-up
(Cen-
sored)
9 6 4 10 19 0 0 0 19
Total cen-
sored
75 74 72 146 221 201 176 377 598
Total
events
54 62 58 120 174 177 202 379 553
Grand to-
tal
129 136 130 266 395 378 378 756 1151
CBZ = carbamazepine, TPM = topiramate
aPrimary reason for discontinuation specified: participants may have withdrawn from allocated treatment for a combination of reasons.
bOther treatment-related failures: drug-related death, pregnancy or perceived remission (SANAD A 2007). Specified only as ’other
reason’ in Privitera 2003.
cOther withdrawals (not treatment-related): epilepsy diagnosis changed and death not related to treatment (SANADA 2007). Specified
only as ’other reason’ in Privitera 2003.
dWithdrawal of consent/participant choice classified as an event in this review but censored in included trial (SANAD A 2007).
Sensitivity analysis classifying withdrawal of consent as a censored observation did not change conclusions (results available on request).
eWithdrawal reasons available for all participants in the two studies but withdrawal times missing for 22 participants in SANAD A
2007 (see Table 2). These 22 participants were not included in analysis of time to treatment failure, but all 22 withdrew for reasons
which would have been censored in analysis, therefore the impact of these missing participants on the analysis is minor.
Table 4. Sensitivity analysis by topiramate dose - Privitera 2003
Outcomea Topiramate
(both arms)
Carbamazepine Topiramate 200
mg
Carbamazepine Topiramate 100
mg
Carbamazepine
n = 226 n = 129 n = 130 n = 129 n = 136 n = 129
Time to treat-
ment failure (any
reason)
HR 1.04 (95% CI 0.75 to 1.42), P
= 0.85
HR 1.03 (95% CI 0.71 to 1.48), P
= 0.89
HR 1.05 (95% CI 0.73 to 1.52), P
= 0.79
Time to treat-
ment failure (ad-
verse events)
HR 0.82 (95% CI 0.53 to 1.27), P
= 0.38
HR 0.92 (95% CI 0.56 to 1.52), P
= 0.75
HR 0.73 (95% CI 0.44 to 1.23), P
= 0.23
Time to
treatment failure
(lack of efficacy)
HR 1.44 (95% CI 0.71 to 2.94), P
= 0.31
HR 1.26 (95% CI 0.56 to 2.89), P
= 0.57
HR 1.60 (95% CI 0.74 to 3.44), P
= 0.24
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Table 4. Sensitivity analysis by topiramate dose - Privitera 2003 (Continued)
Time to first
seizure
HR 1.32 (95% CI 0.96 to 1.81), P
= 0.09
HR 1.34 (95% CI 0.94 to 1.91), P
= 0.11
HR 1.29 (95% CI 0.89 to 1.86), P
= 0.18
Time to 12-
month remission
HR 0.82 (95% CI 0.51 to 1.33), P
= 0.42
HR 0.83 (95% CI 0.48 to 1.44), P
= 0.5
HR 0.79 (95% CI 0.46 to 1.37), P
= 0.41
Time to 6-
month remission
HR 0.88 (95% CI 0.65 to 1.18), P
= 0.39
HR 0.84 (95% CI 0.59 to 1.18), P
= 0.31
HR 0.93 (95% CI 0.66 to 1.31), P
= 0.66
HR = hazard ratio
Table 5. Summary of adverse events experienced
Study and
drug
Privitera 2003 SANAD A 2007
TPM 100 TPM 200 CBZ Total TPM CBZ Total
Number expe-
riencing
adverse events
120 114 111 345 283 260 543
Number of
adverse events
1063 1035 970 3068 2503 1339 3842
Num-
ber of adverse
events per per-
son (range)
1 to 40 1 to 30 1 to 37 NA 1 to 35 1 to 37 NA
Number
of drug related
adverse events
a
578 613 537 1728 NA NA NA
Number of
adverse events
requiring ac-
tion/treat-
ment changeb
76 90 72 238 705 529 1234
Num-
ber of partici-
pants needing
a treat-
ment change/
dose changeb
27 31 32 90 185 173 358
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CBZ = carbamazepine, NA = not available, TPM = topiramate, TPM 100 = topiramate 100 mg/day, TPM 200 = topiramate 200 mg/
day (Privitera 2003)
aDefined as events which are ’very likely,’ ’probably’ or ’possibly’ related in Privitera 2003. Not stated if events were drug-related in
SANAD A 2007.
bInformation given only for drug discontinuation in Privitera 2003. Information on drug discontinuation and dose change in SANAD
A 2007.
Table 6. Most commonly reported adverse events
Most
com-
monly
reported
adverse
eventsa
Privitera 2003 SANAD A 2007 Total
CBZ TPM
100
TPM
200
Total CBZ TPM Total CBZ TPM Total
Aggres-
sion
0 (0) 8 (6) 5 (2) 13 (8) 41 (25) 75 (50) 116 (75) 41 (25) 88 (58) 129 (83)
Anorexia/
weight
loss
32 (16) 45 (26) 54 (34) 131 (76) 16 (14) 126 (82) 142 (96) 48 (30) 225 (142) 273 (172)
Anxiety/
depres-
sion
24 (15) 48 (27) 60 (39) 132 (81) 46 (35) 107 (71) 153 (106) 70 (50) 215 (137) 285 (187)
Aphasia 18 (10) 10 (7) 34 (14) 62 (31) 11 (10) 16 (16) 27 (26) 29 (20) 60 (37) 89 (57)
Ataxia 7 (4) 11 (6) 9 (6) 27 (16) 30 (23) 21 (14) 51 (37) 37 (27) 41 (26) 78 (53)
Chest in-
fection/
bronchi-
tis
36 (23) 41 (25) 54 (26) 131 (74) 6 (6) 3 (3) 9 (9) 42 (29) 98 (54) 140 (83)
Cold/
fever/
influenza
14 (13) 20 (11) 15 (15) 49 (39) 3 (3) 4 (4) 7 (7) 17 (16) 39 (30) 56 (46)
Concen-
tration
6 (5) 15 (7) 28 (11) 49 (23) 11 (11) 8 (7) 19 (18) 17 (16) 51 (25) 68 (41)
Confu-
sion
6 (4) 5 (4) 10 (6) 21 (14) 33 (25) 45 (34) 78 (59) 39 (29) 60 (44) 99 (73)
Dental 6 (3) 10 (7) 9 (5) 25 (15) 17 (14) 13 (13) 30 (27) 23 (17) 32 (25) 55 (42)
Dizzy/
faint
49 (30) 44 (24) 35 (23) 128 (77) 64 (51) 76 (49) 140 (100) 113 (81) 155 (96) 268 (177)
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Table 6. Most commonly reported adverse events (Continued)
Drowsy/
tired
130 (60) 97 (51) 79 (45) 306 (156) 267 (187) 188 (139) 455 (326) 397 (247) 364 (235) 761 (482)
Gastroin-
testinal
distur-
bances
88 (51) 50 (32) 53 (28) 191 (111) 49 (41) 48 (32) 97 (73) 137 (92) 151 (92) 288 (184)
Headache
75 (39) 84 (38) 40 (24) 199 (101) 97 (65) 76 (44) 173 (109) 172 (104) 200 (106) 372 (210)
In-
creased/
worsened
seizures
2 (2) 5 (4) 0 (0) 7 (6) 41 (30) 30 (24) 71 (54) 43 (32) 35 (28) 78 (60)
Kidney/
urinary
problems
11 (6) 15 (7) 22 (12) 48 (25) 10 (10) 21 (15) 31 (25) 21 (16) 58 (34) 79 (50)
Memory 8 (6) 19 (10) 26 (12) 53 (28) 71 (48) 92 (62) 163 (110) 79 (54) 137 (84) 216 (138)
Mood/
be-
havioural
change
19 (10) 22 (14) 29 (15) 70 (39) 56 (42) 97 (76) 153 (118) 75 (52) 148 (105) 223 (157)
Nausea/
vomiting
57 (35) 21 (19) 27 (23) 105 (77) 54 (49) 32 (29) 86 (78) 111 (84) 80 (71) 191 (155)
Pain 26 (19) 14 (9) 39 (19) 79 (47) 15 (13) 20 (17) 35 (30) 41 (32) 73 (45) 114 (77)
Pins and
needles
17 (5) 116 (38) 135 (45) 268 (88) 23 (17) 205 (148) 228 (165) 40 (22) 456 (231) 496 (253)
Rash 61 (35) 42 (22) 25 (17) 128 (74) 99 (81) 54 (44) 153 (125) 160 (116) 121 (83) 281 (199)
Sleep
prob-
lems/
night-
mares
14 (6) 24 (14) 23 (12) 61 (32) 24 (16) 40 (30) 64 (46) 38 (22) 87 (56) 125 (78)
Vision 7 (5) 8 (5) 3 (3) 18 (13) 33 (28) 24 (23) 57 (51) 40 (33) 35 (31) 75 (64)
Weight
gain
8 (3) 5 (4) 0 (0) 13 (7) 42 (27) 25 (15) 67 (42) 50 (30) 30 (19) 80 (49)
CBZ = carbamazepine, TPM = topiramate, TPM 100 = topiramate 100 mg/day, TPM 200 = topiramate 200 mg/day (Privitera 2003)
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a. Results are expressed as Number of events (Number of Participants), where events = number of adverse events reported; participants
= number of participants reporting the adverse event (a participant could report the same type of adverse event multiple times).
Less commonly reported adverse events are not summarised in this table but details are available on request from the review authors.
General terminology for the type of adverse events was defined by the review authors based on the individual participant data provided.
A P P E N D I C E S
Appendix 1. Cochrane Register of Studies (CRS Web) search strategy
1. Topiram* or Tipiram* or Topamax or TPM or qudexy AND CENTRAL:TARGET
2. MeSH DESCRIPTOR Carbamazepine Explode All AND CENTRAL:TARGET
3. Carbamezepin* or CBZ or SPD417 or Amizepine or “Apo-Carbamazepine” or Atretol or Biston or Calepsin or Carbagen or
Carbamazepen* or Carbatrol or Carbazepin* or Carbelan or Epitol or Equetro or Finlepsin or Karbamazepin or Lexin or Neurotol
or “Novo-Carbamaz” or “Nu-Carbamazepine” or Sirtal or Stazepin or Stazepine or “Taro-Carbamazepine” or Tegretal or Tegretol or
Telesmin or Teril or Timonil AND CENTRAL:TARGET
4. #2 OR #3 AND CENTRAL:TARGET
5. #1 AND #4 AND CENTRAL:TARGET
6. ((adjunct* or “add-on” or “add on” or adjuvant* or combination* or polytherap*) not (monotherap* or alone or singl*)):TI AND
CENTRAL:TARGET
7. #5 NOT #6 AND CENTRAL:TARGET
8. MESH DESCRIPTOR Epilepsy EXPLODE ALL AND CENTRAL:TARGET
9. MESH DESCRIPTOR Seizures EXPLODE ALL AND CENTRAL:TARGET
10. (epilep* OR seizure* OR convuls*):AB,KW,MC,MH,TI AND CENTRAL:TARGET
11. #8 OR #9 OR #10 AND CENTRAL:TARGET
12. #7 AND #11
13. >14/04/2016:CRSINCENTRAL AND CENTRAL:TARGET
14. #12 AND #13
Appendix 2. MEDLINE (Ovid) search strategy
This strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomized trials (Lefebvre 2011).
1. (Topiram$ or Tipiramate or Topamax).mp.
2. exp Carbamazepine/
3. (Carbamezepin$ or CBZ or SPD417 or Amizepine or “Apo-Carbamazepine” or Atretol or Biston or Calepsin or Carbagen or
Carbamazepen$ or Carbatrol or Carbazepin$ or Carbelan or Epitol or Equetro or Finlepsin or Karbamazepin or Lexin or Neurotol
or “Novo-Carbamaz” or “Nu-Carbamazepine” or Sirtal or Stazepin or Stazepine or “Taro-Carbamazepine” or Tegretal or Tegretol or
Telesmin or Teril or Timonil).mp.
4. 2 or 3
5. exp Epilepsy/
6. exp Seizures/
7. (epilep$ or seizure$ or convuls$).tw.
8. 5 or 6 or 7
9. exp *Pre-Eclampsia/ or exp *Eclampsia/
10. 8 not 9
11. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
12. clinical trials as topic.sh.
13. trial.ti.
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14. 11 or 12 or 13
15. exp animals/ not humans.sh.
16. 14 not 15
17. 1 and 4 and 10 and 16
18. ((adjunct$ or “add-on” or “add on” or adjuvant$ or combination$ or polytherap$) not (monotherap$ or alone or singl$)).ti.
19. 17 not 18
20. limit 19 to ed=20160414-20180522
21. 19 not (1$ or 2$).ed.
22. 21 and (2016$ or 2017$ or 2018$).dt.
23. 20 or 22
24. remove duplicates from 23
Appendix 3. ClinicalTrials.gov search strategy
Interventional Studies | Epilepsy | Topiramate AND Carbamazepine | First posted on or after 04/14/2016
Appendix 4. ICTRP search strategy
Condition: epilepsy
Intervention: Topiramate AND Carbamazepine
Date of registration between 14/04/2016 and 22/05/2018
WH A T ’ S N E W
Date Event Description
22 May 2018 New search has been performed We updated the searches on 22 May 2018; we have not
included any new trials. We replaced the term ’partial’ by
’focal’, in accordance with the most recent classification
of epilepsies of the International League Against Epilepsy
(Scheffer 2017).
22 May 2018 New citation required but conclusions have not changed Conclusions are unchanged
H I S T O R Y
Protocol first published: Issue 1, 2016
Review first published: Issue 12, 2016
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Date Event Description
26 April 2017 Amended Declarations of interest section updated.
C O N T R I B U T I O N S O F A U T H O R S
SJ Nevitt wrote the text of the protocol with the input of M Sudell, C Tudur Smith and AG Marson.
SJ Nevitt requested all individual participant data (IPD), under the supervision of C Tudur Smith and AG Marson.
SJ Nevitt and M Sudell prepared IPD for analysis, conducted analyses of the review and interpreted results under the supervision of C
Tudur Smith (statistical interpretation) and AG Marson (clinical interpretation).
SJ Nevitt wrote the text of the review with the input of M Sudell, C Tudur Smith and AG Marson.
D E C L A R A T I O N S O F I N T E R E S T
SJN: none known
MS: none known
CTS: none known
AGM: a consortium of pharmaceutical companies (GSK, EISAI, UCB Pharma) funded the National Audit of Seizure Management in
Hospitals (NASH) through grants paid to the University of Liverpool. Professor Tony Marson is part funded by National Institute for
Health Research Collaboration for Leadership in Applied Health Research and Care North West Coast (NIHR CLAHRC NWC).
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute of Health Research (NIHR), UK.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Anticonvulsants [adverse effects; ∗therapeutic use]; Carbamazepine [adverse effects; ∗therapeutic use]; Epilepsies, Partial [∗drug ther-
apy]; Epilepsy, Generalized [drug therapy]; Epilepsy, Tonic-Clonic [∗drug therapy]; Fructose [adverse effects; ∗analogs & derivatives;
therapeutic use]; Induction Chemotherapy; Topiramate
MeSH check words
Humans
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